<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN" "archivearticle.dtd"><article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><front><journal-meta><journal-id journal-id-type="nlm-ta">PLoS ONE</journal-id><journal-id journal-id-type="publisher-id">plos</journal-id><journal-id journal-id-type="pmc">plosone</journal-id><journal-title>PLoS ONE</journal-title><issn pub-type="epub">1932-6203</issn><publisher><publisher-name>Public Library of Science</publisher-name><publisher-loc>San Francisco, USA</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">07-PONE-RA-02606R1</article-id><article-id pub-id-type="doi">10.1371/journal.pone.0001592</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="Discipline"><subject>Cell Biology/Cell Adhesion</subject><subject>Cell Biology/Cell Growth and Division</subject><subject>Cell Biology/Cell Signaling</subject><subject>Cell Biology/Cellular Death and Stress Responses</subject><subject>Cell Biology/Chemical Biology of the Cell</subject><subject>Molecular Biology/Bioinformatics</subject><subject>Molecular Biology/Translation Mechanisms</subject><subject>Molecular Biology/Translational Regulation</subject><subject>Oncology/Breast Cancer</subject><subject>Pathology/Histopathology</subject><subject>Surgery/Breast Surgery</subject><subject>Women's Health/Breast Cancer</subject></subj-group></article-categories><title-group><article-title>Induction of ErbB-3 Expression by &#x003b1;6&#x003b2;4 Integrin Contributes to Tamoxifen Resistance in ER&#x003b2;1-Negative Breast Carcinomas</article-title><alt-title alt-title-type="running-head">PI3K and TAM Resistance</alt-title></title-group><contrib-group><contrib contrib-type="author" equal-contrib="yes"><name><surname>Folgiero</surname><given-names>Valentina</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" equal-contrib="yes"><name><surname>Avetrani</surname><given-names>Paolo</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Bon</surname><given-names>Giulia</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Di Carlo</surname><given-names>Selene E.</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Fabi</surname><given-names>Alessandra</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>Nistic&#x000f2;</surname><given-names>Cecilia</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>Vici</surname><given-names>Patrizia</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>Melucci</surname><given-names>Elisa</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref></contrib><contrib contrib-type="author"><name><surname>Buglioni</surname><given-names>Simonetta</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref></contrib><contrib contrib-type="author"><name><surname>Perracchio</surname><given-names>Letizia</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref></contrib><contrib contrib-type="author"><name><surname>Sperduti</surname><given-names>Isabella</given-names></name><xref ref-type="aff" rid="aff4"><sup>4</sup></xref></contrib><contrib contrib-type="author"><name><surname>Rosan&#x000f2;</surname><given-names>Laura</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Sacchi</surname><given-names>Ada</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Mottolese</surname><given-names>Marcella</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref></contrib><contrib contrib-type="author"><name><surname>Falcioni</surname><given-names>Rita</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="corresp" rid="cor1"><sup>&#x0002a;</sup></xref></contrib></contrib-group><aff id="aff1"><label>1</label><addr-line>Department of Experimental Oncology, Regina Elena Cancer Institute, Rome, Italy</addr-line></aff><aff id="aff2"><label>2</label><addr-line>Department of Medical Oncology, Regina Elena Cancer Institute, Rome, Italy</addr-line></aff><aff id="aff3"><label>3</label><addr-line>Department of Pathology, Regina Elena Cancer Institute, Rome, Italy</addr-line></aff><aff id="aff4"><label>4</label><addr-line>Scientific Direction, Regina Elena Cancer Institute, Rome, Italy</addr-line></aff><contrib-group><contrib contrib-type="editor"><name><surname>Jin</surname><given-names>Dong-Yan</given-names></name><role>Academic Editor</role><xref ref-type="aff" rid="edit1"/></contrib></contrib-group><aff id="edit1">University of Hong Kong, China</aff><author-notes><corresp id="cor1">&#x0002a;E-mail: <email>falcioni@ifo.it</email></corresp><fn fn-type="con"><p>Conceived and designed the experiments: RF. Performed the experiments: MM VF PA GB SD SB. Analyzed the data: MM IS. Contributed reagents/materials/analysis tools: AF CN PV EM LP LR. Wrote the paper: RF. Other: Critical discussion: MM AS.</p></fn></author-notes><pub-date pub-type="collection"><year>2008</year></pub-date><pub-date pub-type="epub"><day>13</day><month>2</month><year>2008</year></pub-date><volume>3</volume><issue>2</issue><elocation-id>e1592</elocation-id><history><date date-type="received"><day>29</day><month>10</month><year>2007</year></date><date date-type="accepted"><day>18</day><month>1</month><year>2008</year></date></history><copyright-statement>Folgiero et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</copyright-statement><copyright-year>2008</copyright-year><abstract><sec><title>Background</title><p>Tamoxifen is still the most widely used drug in hormone therapy for the treatment of breast cancer. Its benefits in adjuvant treatment are well documented in controlled and randomized clinical studies, which have demonstrated an increase in disease-free intervals of patients with positive hormonal receptors. However, the mechanisms involved in endocrine resistance are not clear. Laboratory and clinical data now indicate that bi-directional molecular cross-talk between nuclear or membrane ER and growth factor receptor pathways may be involved in endocrine resistance. We recently found a functional interaction between &#x003b1;6&#x003b2;4 integrin and ErbB-3 receptor to maintain the PI3K/Akt survival pathway of mammary tumour cells. We sought to improve understanding of this process in order to provide the involvement of both receptors insight into mechanism of Tamoxifen resistance.</p></sec><sec><title>Methods and Findings</title><p>Using human breast cancer cell lines displaying different levels of &#x003b1;6&#x003b2;4 and ErbB-3 receptors and a series of 232 breast cancer biopsies from patients submitted to adjuvant Tamoxifen monotherapy for five years, we evaluated the functional interaction between both receptors in relationship to Tamoxifen responsiveness. In mammary carcinoma cells, we evidenced that the &#x003b1;6&#x003b2;4 integrin strongly influence Akt phosphorylation through ErbB-3 protein regulation. Moreover, the ErbB-3 inactivation inhibits Akt phosphorylation, induces apoptosis and inhibits <italic>in vitro</italic> invasion favouring Tamoxifen responsiveness. The analysis of human tumors revealed a significant relationship between &#x003b1;6&#x003b2;4 and ErbB-3 in P-Akt-positive and ER&#x003b2;1-negative breast cancers derived from patients with lower disease free survival.</p></sec><sec><title>Conclusions</title><p>We provided evidence that a strong relationship occurs between &#x003b1;6&#x003b2;4 and ErbB-3 positivity in ER&#x003b2;1-negative breast cancers. We also found that the association between ErbB-3 and P-Akt positivity mainly occurs in ER&#x003b2;1-negative breast cancer derived from patients with lower DFS indicating that both receptors are clinically relevant in predicting the response to Tamoxifen.</p></sec></abstract><counts><page-count count="12"/></counts></article-meta></front><body><sec id="s1"><title>Introduction</title><p>In many breast cancer (BC), activation of the phosphatidylinositol 3-kinase (PI3K) pathway may deeply reduce the efficacy to targeted therapies <xref ref-type="bibr" rid="pone.0001592-Hynes1">&#x0005b;1&#x0005d;</xref>&#x02013;<xref ref-type="bibr" rid="pone.0001592-Harrari1">&#x0005b;3&#x0005d;</xref>. In the last few years, a strong activation of the PI3-K/Akt signaling pathway was observed in tumor cells that express high levels of integrin &#x003b1;6&#x003b2;4, a laminin receptor implicated in tumor progression and invasion <xref ref-type="bibr" rid="pone.0001592-Shaw1">&#x0005b;4&#x0005d;</xref>&#x02013;<xref ref-type="bibr" rid="pone.0001592-Bachelder1">&#x0005b;9&#x0005d;</xref>. The involvement of this integrin in tumor progression is supported by large experimental evidence. In mammary and ovary carcinoma cell lines, &#x003b1;6&#x003b2;4 integrin associates with ErbB-2 overexpression and co-operates to promote a PI3K-dependent invasion and survival <xref ref-type="bibr" rid="pone.0001592-Falcioni1">&#x0005b;10&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0001592-Gambaletta1">&#x0005b;6&#x0005d;</xref>. In MMTV-Neu mice, the introduction of a targeted deletion of the &#x003b2;4 cytoplasmic domain revealed that &#x003b2;4 integrin promotes tumor progression cooperating with ErbB-2 signaling <xref ref-type="bibr" rid="pone.0001592-Guo1">&#x0005b;11&#x0005d;</xref>. Inactivation of &#x003b1;6&#x003b2;4 integrin by RNA interference inhibits tumor growth both <italic>in vitro</italic> and <italic>in vivo</italic><xref ref-type="bibr" rid="pone.0001592-Bon2">&#x0005b;12&#x0005d;</xref>&#x02013;<xref ref-type="bibr" rid="pone.0001592-Bertotti1">&#x0005b;14&#x0005d;</xref> and strongly reduces the activity of the PI3K pathway inducing apoptosis upon hormone deprivation and TAM treatment in MCF7 BC cells <xref ref-type="bibr" rid="pone.0001592-Bon2">&#x0005b;12&#x0005d;</xref>. In addition, we have recently evidenced that the &#x003b1;6&#x003b2;4-induced PI3K-dependent survival pathway of two different BC cell lines is due to the capability of &#x003b1;6&#x003b2;4 integrin to enhance ErbB-3 expression. This enhancement results in an increase of ErbB-2/ErbB-3 heterodimerization and consequently in the activation of the PI3K survival pathway <xref ref-type="bibr" rid="pone.0001592-Folgiero1">&#x0005b;15&#x0005d;</xref>. Collectively, these studies suggest a strong cooperation between &#x003b1;6&#x003b2;4 integrin and EGFR family members in mammary tumors and highlight a pathway by which this integrin might contribute to BC tumorigenicity and responsiveness to treatments.</p><p>BC remains one of the most heterogeneous tumors in terms of capability to give metastases, expression of hormone receptors and responsiveness to therapies and is the first cause of death for women aged 35&#x02013;45 years <xref ref-type="bibr" rid="pone.0001592-Jemal1">&#x0005b;16&#x0005d;</xref>. Tamoxifen (TAM) is still the most widely used drug in hormone therapy for the treatment of this neoplasia. Its benefits in adjuvant treatment and metastatic disease are well documented in controlled and randomized clinical studies, which have demonstrated an increase in disease-free intervals and overall survival of patients with positive hormonal receptors <xref ref-type="bibr" rid="pone.0001592-Ryden1">&#x0005b;17&#x0005d;</xref>. However, endocrine therapies do not always work in patients, despite the presence of hormone receptors in their tumors <xref ref-type="bibr" rid="pone.0001592-Osborne1">&#x0005b;18&#x0005d;</xref>. Originally, only estrogen receptor (ER) &#x003b1; and progesterone receptor (PgR) were thought to be involved in hormone signaling. However, a second ER, termed ER&#x003b2;, was subsequently discovered, adding another dimension of complexity to the regulation of hormone response <xref ref-type="bibr" rid="pone.0001592-Kuiper1">&#x0005b;19&#x0005d;</xref>&#x02013;<xref ref-type="bibr" rid="pone.0001592-Schiff1">&#x0005b;20&#x0005d;</xref>. Insights into the mechanisms of endocrine therapy resistance, although still cause for debate, have come from several studies concerning the biology of ERs and the various signaling pathways in the cell with which they communicate. Laboratory and clinical data now indicate that bidirectional molecular cross-talk between nuclear or membrane ER and growth factor receptor pathways may be involved in endocrine resistance <xref ref-type="bibr" rid="pone.0001592-Grunt1">&#x0005b;21&#x0005d;</xref>. An understanding of these ER activities at the molecular level may yield new strategies to prevent or overcome resistance to TAM and other forms of treatment.</p><p>In the present work, using ER-positive human BC cell lines, we investigated the functional interaction between &#x003b1;6&#x003b2;4 and ErbB-3 proteins in relationship to TAM responsiveness. In addition, with the aim to translate our <italic>in vitro</italic> study to an <italic>in vivo</italic> model, we carried out immunohistochemical (IHC) analysis to evaluate the functional relationship between desease-free survival (DFS) and expression of &#x003b1;6&#x003b2;4, ErbB-2, ErbB-3, P-Akt and ER&#x003b2;1 in a retrospective series of 232 ER&#x003b1; and/or PgR positive BCs derived from patients which had been homogeneously submitted to adjuvant TAM monotherapy. Combining our analyses, we provide evidence that &#x003b1;6&#x003b2;4 expression is functionally associated with ErbB-3 and P-Akt molecules <italic>in vitro</italic>. However, even though &#x003b1;6&#x003b2;4 expression <italic>in vivo</italic> is still strongly associated with ErbB-3 positivity and ER&#x003b2;1 negativity, it does not influence patient outcome. Interestingly, we report for the first time a strong association of ErbB-3 and P-Akt positivity that mainly occurs in ER&#x003b2;1 negative BC derived from patients with lower DFS. This result suggests that both receptors are clinically relevant in predicting the response to Tamoxifen treatment.</p></sec><sec id="s2"><title>Results</title><sec id="s2a"><title>Expression of &#x003b2;4, ErbB-2, ErbB-3, ER&#x003b1; and ER&#x003b2; receptors in mammary tumor cell lines</title><p>We first evaluated the expression level of ER&#x003b1; and ER&#x003b2;, &#x003b2;4 integrin subunit, ErbB2, and ErbB-3 in a series of human mammary tumor cell lines including MDA-MB 231, MDA-MB 361, SKBr3, BT474, BT549, and T47D. Analysis of ER&#x003b1; by Western blotting (<xref ref-type="fig" rid="pone-0001592-g001">Figure 1A</xref>) and ER&#x003b2;1 by RT-PCR, using specific primers to detect ER&#x003b2;1 mRNA, (<xref ref-type="fig" rid="pone-0001592-g001">Figure 1B</xref>) showed that BT549 cells were negative for both ERs whereas the other cell lines were positive for at least one ER. Then, the expression of ER&#x003b2;1 protein was evaluated by immunocytochemistry (<xref ref-type="supplementary-material" rid="pone.0001592.s001">Figure S1</xref>). The data obtained confirmed the expression of ER&#x003b2;1 protein in each cell line that resulted positive for ER&#x003b2;1 mRNA. As expected, the analysis of the other receptors by cytofluorimetry showed that MDA-MB 361, SKBr3 and BT474 and T47D cells express considerable levels of ErbB-2 protein (<xref ref-type="fig" rid="pone-0001592-g001">Figure 1C</xref>) <xref ref-type="bibr" rid="pone.0001592-Pasleau1">&#x0005b;22&#x0005d;</xref>. Moreover, the same cells express &#x003b2;4 and ErbB-3 proteins at comparable levels, whereas BT549 and MDA-MB 231 cells displaying low levels of ErbB-2 and &#x003b2;4 proteins were also ErbB-3 negative, supporting our recent finding that &#x003b2;4 overexpression regulates ErbB-3 protein at translational level <xref ref-type="bibr" rid="pone.0001592-Folgiero1">&#x0005b;15&#x0005d;</xref>.</p><fig id="pone-0001592-g001" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0001592.g001</object-id><label>Figure 1</label><caption><title>Expression of &#x003b2;4, ErbB-2, ErbB-3 and ER&#x003b1; and &#x003b2;1 receptors in mammary tumor cell lines.</title><p>A. The expression of ER&#x003b1; was evaluated by western blot analysis. The anti-actin Ab was used to validate equivalent loading protein. B. ER&#x003b2;1 expression was evaluated by RT-PCR from total mRNA extracted from the indicated cell lines using primers specific for human ER&#x003b2;1 and the housekeeping aldolase genes. C. Mammary tumor cell lines MDA-MB 231, MDA-MB 361, SKBr3, BT474, BT549 and T47D were analyzed by FACS to reveal the expression level of &#x003b2;4 integrin subunit, ErbB-2 and ErbB-3 receptors.</p></caption><graphic xlink:href="pone.0001592.g001"/></fig><sec id="s2a1"><title>The regulation of ErbB-3 expression by &#x003b1;6&#x003b2;4 influences AKT activation</title><p>Given that &#x003b1;6&#x003b2;4 integrin is the receptor for laminin 5 (LM5) and, as we previously demonstrated, ligation of the integrin to this substrate enhances PI3K signaling, we first verified the level of Akt phosphorylation upon stimulation in the mammary tumor cell lines. To this end, MDA-MB 361, BT474, SKBr3, BT549 and MDA-MB 231 cells were spread onto LM5 for 20 minutes and the level of Akt activity was evaluated by Ser473 phosphorylation. As reported in <xref ref-type="fig" rid="pone-0001592-g002">Figure 2A</xref>, a strong enhancement of Akt phosphorylation was detectable in the cells expressing &#x003b1;6&#x003b2;4, ErbB-2 and ErbB-3 receptors (i.e., MDA-MB 361, BT474 and SKBr3 cells) while, it did not occur in cells expressing low levels of &#x003b2;4, ErbB-2 and undectable level of ErbB-3 (i.e., BT549 and MDA-MB 231) (<xref ref-type="fig" rid="pone-0001592-g002">Figure 2A</xref>). As expected, after 60 minutes of LM5 stimulation, the phosphorylation of Akt returned to the basal levels (data not shown).</p><fig id="pone-0001592-g002" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0001592.g002</object-id><label>Figure 2</label><caption><title>The &#x003b1;6&#x003b2;4 influence Akt activation by ErbB-3.</title><p>A. BT549, MDA-MB 231, MDA-MB 361, BT474 and SKBr3 cells were serum-starved for 24 hrs and then the cells were spread onto LM5 and extracted in detergent. Equivalent amounts of protein were separated by SDS-PAGE and analyzed by immunobloting to evaluate the relative expression of &#x003b2;4 and phospho-Akt. Total-Akt Ab was used to validate equivalent loading of protein in each lane. B. MDA-MB 361, BT474 and SKBr3 cells were transiently transfected for 48 hrs with either scrambled or specific &#x003b2;4-shRNA and ErbB-3 siRNA. The cells were then serum-starved for 24 hrs and extracted in detergent. Equivalent amounts of protein were separated by SDS-PAGE and analyzed by immunobloting to evaluate the relative expression of &#x003b2;4, ErbB-3 and phospho-Akt. Hsp70 Ab was used to validate equivalent loading of protein in each lane.</p></caption><graphic xlink:href="pone.0001592.g002"/></fig><p>To confirm the essential role of ErbB-3 protein in the activation of Akt by &#x003b1;6&#x003b2;4, a &#x003b2;4 shRNA (&#x003b2;4si) or an ErbB-3 siRNA (B3si) were expressed in MDA-MB 361, BT474 and SKBr3 cells, as previously described <xref ref-type="bibr" rid="pone.0001592-Folgiero1">&#x0005b;15&#x0005d;</xref>. As expected, depletion of &#x003b2;4 resulted in a strong reduction of &#x003b2;4 compared to the levels found in scramble (scr) control cells. Of interest, &#x003b2;4 depletion also caused a strong reduction of ErbB-3 expression and Akt phosphorylation (<xref ref-type="fig" rid="pone-0001592-g002">Figure 2B</xref>, upper panel). Moreover, ErbB-3 depletion resulted in a strong reduction of ErbB-3 expression and, at the same time, of Akt phosphorylation (<xref ref-type="fig" rid="pone-0001592-g002">Figure 2B</xref>, lower panel). Since &#x003b1;6&#x003b2;4 regulates ErbB-3 level and the depletion of either &#x003b2;4 or ErbB-3 proteins resulted in a strong inhibition of Akt activation, the data confirm the essential role of ErbB-3 in the activation of Akt by &#x003b1;6&#x003b2;4 integrin in mammary tumor cells (<xref ref-type="fig" rid="pone-0001592-g002">Figure 2B</xref>).</p></sec><sec id="s2a2"><title>ErbB-3 depletion causes apoptosis and inhibits <italic>in vitro</italic> invasion favoring TAM responsiveness</title><p>To further evaluate the function of ErbB-3 in the PI3K survival pathway, we analyzed cell death and apoptosis in the absence of hormones and under TAM treatment of ErbB3 positive (SKBr3, MDA-MB 361, BT474 and T47D) and ErbB3 negative (MDAMB231) cell lines. As shown in <xref ref-type="fig" rid="pone-0001592-g003">Figure 3A and 3B</xref>, in the absence of hormones, depletion of ErbB-3 protein caused <italic>per se</italic> a strong cell death compared to scr cells (SKBr3/B3i 32&#x00025; vs SKBr3/scr 8&#x00025;, p&#x0200a;&#x0003d;&#x0200a;0.001; MDA MB361/B3i 42&#x00025; vs MDA MB361/scr 6&#x00025;, p&#x0003c;0.0001; BT474/B3i 35&#x00025; vs BT474/scr 11&#x00025;, p&#x0200a;&#x0003d;&#x0200a;0.04; T47D/B3i 39&#x00025; vs T47D/scr 7&#x00025;, p&#x0200a;&#x0003d;&#x0200a;0.04). Cell death was further increased by TAM treatment (SKBr3/B3si/TAM 48&#x00025; vs SKBr3/scr/TAM 19&#x00025;, p&#x0003c;0.0001; MDA MB361/B3si/TAM 55&#x00025; vs MDA MB361/scr/TAM 21&#x00025;, p&#x0003c;0.0001; BT474/B3si/TAM 38&#x00025; vs BT474/scr/TAM 18&#x00025;, p&#x0200a;&#x0003d;&#x0200a;0.02; T47D/B3si/TAM 42&#x00025; vs T47D/scr/TAM 10&#x00025;, p&#x0200a;&#x0003d;&#x0200a;0.005) as also assessed by cleavage of PARP, a marker of apoptotic death (<xref ref-type="fig" rid="pone-0001592-g003">Fig. 3B</xref>). The results we obtained on cell death and apoptosis on T47D cells strongly reinforce our hypothesis that ErbB-3 sustains the survival function of mammary tumor cells in the absence of hormone stimuli. Indeed, this cell line is negative for ER&#x003b2;1 expression, does not respond to TAM treatment, and undergoes apoptosis only upon ErbB-3 depletion. MDAMB231 cells that are ErbB-3 negative, even if are ER&#x003b2;1 positive, do not respond to TAM treatment and proliferate and survive as well as untreated cells (p&#x0200a;&#x0003d;&#x0200a;0.82) (<xref ref-type="fig" rid="pone-0001592-g003">Fig. 3A,B</xref>), indicating that these cells have developed other survival pathway(s).</p><fig id="pone-0001592-g003" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0001592.g003</object-id><label>Figure 3</label><caption><title>ErbB-3 expression influences survival and invasion of mammary tumor cells treated under TAM treatment.</title><p>A. SKBr3, MDA-MB 361, BT474, T47D and MDAMB231 cells after three days of hormone deprivation were transiently transfected with either scrambled or specific ErbB-3 siRNA. Where specified, 24 hrs after transfection scrambled and ErbB3 interfered cells were pre-incubated for 24 hours at 37&#x000b0;C with TAM 2.5 &#x000b5;M. 48 hours following transfection, the cell death was evaluated by Trypan-blue exclusion. Statistical differences were evaluated by T test (p&#x0003c;0.05). B. Equivalent amounts of total cell lysate derived from the cell lines described in A were separated by SDS-PAGE and analyzed by immunobloting to evaluate the expression level of PARP cleavage. Hsp70 Ab was used to validate equivalent loading of protein in each lane. C. SKBr3, MDA-MB 361, BT474, T47D and MDAMB231 cells transfected as described in A were assayed for their ability to invade matrigel in the absence of hormone and under TAM treatment. Statistical differences were evaluated by T test (p&#x0003c;0.05).</p></caption><graphic xlink:href="pone.0001592.g003"/></fig><p>It is widely reported that TAM resistance and, as a consequence, tumor progression may be also due to PI3K activation <xref ref-type="bibr" rid="pone.0001592-FresnoVara1">&#x0005b;23&#x0005d;</xref>. In order to understand the role of ErbB-3 in the invasion process, we evaluated the invasive capability of scr and ErbB-3-depleted SKBr3, MDA-MB-361, BT474, T47D cells in the absence of hormones and upon TAM treatment. As shown in <xref ref-type="fig" rid="pone-0001592-g003">Figure 3C</xref>, depletion of ErbB-3 protein caused <italic>per se</italic> a strong inhibition of the invasion compared to scr cells (percent of invasion: SKBr3/B3si 50&#x00025; vs SKBr3/scr 100&#x00025;, P&#x0200a;&#x0003d;&#x0200a;0.001; MDA MB361/B3si 54&#x00025; vs MDA MB361/scr 100&#x00025;, p&#x0003c;0.0001; BT474/B3si 70&#x00025; vs BT474/scr 100&#x00025;, p&#x0200a;&#x0003d;&#x0200a;0.03; T47D/B3si 62&#x00025; vs T47D/scr 100&#x00025;, p&#x0200a;&#x0003d;&#x0200a;0.04). The inhibition of the invasion in ErbB-3-depleted cells further increased following TAM treatment compared to scr cells (percent of invasion: SKBr3/B3si/TAM 35&#x00025; vs SKBr3/scr/TAM 85&#x00025;, p&#x0003c;0.0001; MDA MB361/B3si/TAM 42&#x00025; vs MDA MB361/scr/TAM 82&#x00025;, p&#x0003c;0.0001; BT474/B3si/TAM 61&#x00025; vs BT474/scrTAM 83&#x00025;, p&#x0200a;&#x0003d;&#x0200a;0.04; T47D/B3si/TAM 50&#x00025; vs T47D/scr/TAM 90&#x00025;, p&#x0003c;0.001). As expected, TAM treatment does not alters the capability of MDAMB231 cells to invade matrigel (p&#x0200a;&#x0003d;&#x0200a;0.06) (<xref ref-type="fig" rid="pone-0001592-g003">Figure 3C</xref>). Representative invading stained cells are showed on <xref ref-type="supplementary-material" rid="pone.0001592.s002">Figure S2</xref>. Collectively, these data indicate a role of ErbB-3 protein in the mechanisms that regulate the invasion of mammary tumor cells. Since we have previously demonstrated that &#x003b2;4 depletion reduces the responsiveness of mammary tumor cells to TAM treatment, our data also suggest that a cooperative signaling between ErbB-3 and &#x003b1;6&#x003b2;4 integrin could influence resistance to hormone therapy <italic>in vivo</italic>.</p></sec></sec><sec id="s2b"><title>Immunohistochemical analysis of &#x003b2;4 integrin subunit, ErbB-3, ErbB-2, P-Akt, and ER&#x003b2;1 in human primary BC</title><p>To verify whether the functional interaction between &#x003b1;6&#x003b2;4 integrin and ErbB-3 receptor also occurred <italic>in vivo</italic>, we studied 232 biopsies of BC patients surgically treated at our Institute and submitted to adjuvant TAM therapy. The detailed clinicopathological characteristics of the patients are described in <xref ref-type="table" rid="pone-0001592-t001">Table 1</xref>. These tumors were first analyzed by IHC for the expression of &#x003b2;4 integrin subunit, ErbB-3, ErbB-2, ER&#x003b2;1 and P-Akt expression. As summarized in <xref ref-type="fig" rid="pone-0001592-g004">Figure 4A</xref>, of the 232 cases analyzed, &#x003b2;4 exhibited a strong homogeneous (score 2) or heterogeneous (score 1) immunoreaction in 170 BC (73,3&#x00025;). 77 BC (33,2&#x00025;) overexpressed ErbB-3 and 158 (68,1&#x00025;) were ER&#x003b2;1 positive. Moreover, we found that 136 BC (59&#x00025;) were P-Akt positive, while 59 (25,4&#x00025;) were positive for ErbB-2. Representative immunohistochemically positive cases for &#x003b2;4, ErbB-3, P-Akt, ER&#x003b2;1 and ErbB-2 and control tissue sections are shown in <xref ref-type="fig" rid="pone-0001592-g004">Figure 4B</xref>.</p><fig id="pone-0001592-g004" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0001592.g004</object-id><label>Figure 4</label><caption><title>Immunohistochemical analysis of &#x003b2;4, ErbB-3, P-Akt, ER&#x003b2;1 and ErbB-2 in 232 primary BC.</title><p>A. Distribution (&#x00025;) of the bio-pathological factors &#x003b2;4 integrin subunit, ErbB-3, P-Akt(ser473), ER&#x003b2;1 and ErbB-2 in 232 TAM treated breast cancers. B. Representative immunohistochemically positive cases for &#x003b2;4, ErbB-3, P-Akt(ser473), ER&#x003b2;1 and ErbB-2 protein detection and control tissue sections.</p></caption><graphic xlink:href="pone.0001592.g004"/></fig><table-wrap id="pone-0001592-t001" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0001592.t001</object-id><label>Table 1</label><caption><title>Clinicopathological characteristics of 232 invasive breast carcinomas TAM treated</title></caption><graphic id="pone-0001592-t001-1" xlink:href="pone.0001592.t001"/><table frame="hsides" rules="groups" alternate-form-of="pone-0001592-t001-1"><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup><thead><tr><td align="left" rowspan="1" colspan="1">CHARACTERISTIC</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">&#x00025;</td></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1"><bold>Number of patients</bold></td><td align="left" rowspan="1" colspan="1"><bold>232</bold></td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Mean age</bold></td><td align="left" rowspan="1" colspan="1"><bold>63</bold></td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Menopausal</bold></td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Pre</td><td align="left" rowspan="1" colspan="1">25</td><td align="left" rowspan="1" colspan="1">10.8</td></tr><tr><td align="left" rowspan="1" colspan="1">Post</td><td align="left" rowspan="1" colspan="1">207</td><td align="left" rowspan="1" colspan="1">89.2</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Histotype</bold></td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Invasive ductal carcinoma</td><td align="left" rowspan="1" colspan="1">193</td><td align="left" rowspan="1" colspan="1">83.2</td></tr><tr><td align="left" rowspan="1" colspan="1">Invasive lobular carcinoma</td><td align="left" rowspan="1" colspan="1">28</td><td align="left" rowspan="1" colspan="1">12.1</td></tr><tr><td align="left" rowspan="1" colspan="1">Tubular carcinoma</td><td align="left" rowspan="1" colspan="1">7</td><td align="left" rowspan="1" colspan="1">3</td></tr><tr><td align="left" rowspan="1" colspan="1">Papillary carcinoma</td><td align="left" rowspan="1" colspan="1">4</td><td align="left" rowspan="1" colspan="1">1.7</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Tumor size</bold></td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">T1</td><td align="left" rowspan="1" colspan="1">176</td><td align="left" rowspan="1" colspan="1">79.9</td></tr><tr><td align="left" rowspan="1" colspan="1">T2</td><td align="left" rowspan="1" colspan="1">51</td><td align="left" rowspan="1" colspan="1">22</td></tr><tr><td align="left" rowspan="1" colspan="1">T3,T4</td><td align="left" rowspan="1" colspan="1">5</td><td align="left" rowspan="1" colspan="1">2.1</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Lymph node status</bold></td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Negative</td><td align="left" rowspan="1" colspan="1">193</td><td align="left" rowspan="1" colspan="1">83.2</td></tr><tr><td align="left" rowspan="1" colspan="1">Positive</td><td align="left" rowspan="1" colspan="1">39</td><td align="left" rowspan="1" colspan="1">16.8</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Grading</bold></td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">G1</td><td align="left" rowspan="1" colspan="1">53</td><td align="left" rowspan="1" colspan="1">22.8</td></tr><tr><td align="left" rowspan="1" colspan="1">G2</td><td align="left" rowspan="1" colspan="1">141</td><td align="left" rowspan="1" colspan="1">60.8</td></tr><tr><td align="left" rowspan="1" colspan="1">G3</td><td align="left" rowspan="1" colspan="1">38</td><td align="left" rowspan="1" colspan="1">16.4</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>ER&#x003b1;</bold></td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Negative (&#x02264;10&#x00025;)</td><td align="left" rowspan="1" colspan="1">25</td><td align="left" rowspan="1" colspan="1">10.8</td></tr><tr><td align="left" rowspan="1" colspan="1">Positive (&#x0003e;10&#x00025;)</td><td align="left" rowspan="1" colspan="1">207</td><td align="left" rowspan="1" colspan="1">89.2</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>PgR</bold></td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Negative (&#x02264;10&#x00025;)</td><td align="left" rowspan="1" colspan="1">55</td><td align="left" rowspan="1" colspan="1">23.7</td></tr><tr><td align="left" rowspan="1" colspan="1">Positive (&#x0003e;10&#x00025;)</td><td align="left" rowspan="1" colspan="1">177</td><td align="left" rowspan="1" colspan="1">76.3</td></tr></tbody></table><table-wrap-foot><fn id="nt101"><label>&#x0002a;</label><p>range 39&#x02013;95</p></fn></table-wrap-foot></table-wrap></sec><sec id="s2c"><title>Relationship among &#x003b2;4 integrin subunit, pathological and biological parameters</title><p><xref ref-type="table" rid="pone-0001592-t002">Table 2</xref> summarizes the associations between &#x003b2;4 expression and biopathological factors in our series of 232 BC patients. We found that all tumors, which were positive for ErbB-3 receptor, showed a higher score in &#x003b2;4 expression, &#x003b2;4 immunoreaction being significantly associated to ErbB-3 (p&#x0200a;&#x0003d;&#x0200a;0.003). Interestingly, we also found that the majority of high &#x003b2;4-positive tumors were ER&#x003b2;1-negative (p&#x0003c;0.0001). In contrast, &#x003b2;4 was not significantly related to P-Akt, ErbB-2 protein and any conventional pathological parameters, namely tumor size, grading and nodal status.</p><table-wrap id="pone-0001592-t002" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0001592.t002</object-id><label>Table 2</label><caption><title>Relationship between integrin &#x003b2;<sub>4 </sub>expression and biopathological factors in 232 TAM treated breast cancer patients.</title></caption><graphic id="pone-0001592-t002-2" xlink:href="pone.0001592.t002"/><table frame="hsides" rules="groups" alternate-form-of="pone-0001592-t002-2"><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup><thead><tr><td align="left" rowspan="1" colspan="1">Factors</td><td colspan="3" align="left" rowspan="1">Integrin &#x003b2;<sub>4</sub></td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Neg and &#x00025;</td><td align="left" rowspan="1" colspan="1">Low and High Pos and &#x00025;</td><td align="left" rowspan="1" colspan="1">P<xref ref-type="table-fn" rid="nt102">0</xref></td></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1"><bold>Tumor size</bold></td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">T1</td><td align="left" rowspan="1" colspan="1">45 (25.6)</td><td align="left" rowspan="1" colspan="1">131 (74.4)</td><td align="left" rowspan="1" colspan="1">0.48</td></tr><tr><td align="left" rowspan="1" colspan="1">T2-T4</td><td align="left" rowspan="1" colspan="1">17 (30.4)</td><td align="left" rowspan="1" colspan="1">39 (69.6)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Lymph node status</bold></td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Negative</td><td align="left" rowspan="1" colspan="1">48 (24.9)</td><td align="left" rowspan="1" colspan="1">145 (75.1)</td><td align="left" rowspan="1" colspan="1">0.16</td></tr><tr><td align="left" rowspan="1" colspan="1">Positive</td><td align="left" rowspan="1" colspan="1">14 (35.9)</td><td align="left" rowspan="1" colspan="1">25 (64.1)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Grading</bold></td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">G1</td><td align="left" rowspan="1" colspan="1">11 (20.8)</td><td align="left" rowspan="1" colspan="1">42 (79.2)</td><td align="left" rowspan="1" colspan="1">0.51</td></tr><tr><td align="left" rowspan="1" colspan="1">G2</td><td align="left" rowspan="1" colspan="1">41 (29.1)</td><td align="left" rowspan="1" colspan="1">100 (70.9)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">G3</td><td align="left" rowspan="1" colspan="1">10 (26.3)</td><td align="left" rowspan="1" colspan="1">28 (73.7)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"><bold>ErbB-3</bold></td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Negative</td><td align="left" rowspan="1" colspan="1">51 (33)</td><td align="left" rowspan="1" colspan="1">104 (67)</td><td align="left" rowspan="1" colspan="1"><bold>0.003</bold></td></tr><tr><td align="left" rowspan="1" colspan="1">Positive</td><td align="left" rowspan="1" colspan="1">11 (14)</td><td align="left" rowspan="1" colspan="1">66 (86)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"><bold>P-Akt (ser473)</bold></td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">0.19</td></tr><tr><td align="left" rowspan="1" colspan="1">Negative</td><td align="left" rowspan="1" colspan="1">30 (31.6)</td><td align="left" rowspan="1" colspan="1">65 (68.4)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Low</td><td align="left" rowspan="1" colspan="1">21 (22.8)</td><td align="left" rowspan="1" colspan="1">56 (77.2)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">High</td><td align="left" rowspan="1" colspan="1">11 (18)</td><td align="left" rowspan="1" colspan="1">49 (82)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"><bold>ER &#x003b2;1</bold></td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Negative</td><td align="left" rowspan="1" colspan="1">32 (43.2)</td><td align="left" rowspan="1" colspan="1">42 (56.8)</td><td align="left" rowspan="1" colspan="1"><bold>&#x0003c;0.0001</bold></td></tr><tr><td align="left" rowspan="1" colspan="1">Positive</td><td align="left" rowspan="1" colspan="1">30 (19)</td><td align="left" rowspan="1" colspan="1">128 (81)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"><bold>ErbB-2</bold></td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Negative</td><td align="left" rowspan="1" colspan="1">50 (28.9)</td><td align="left" rowspan="1" colspan="1">123 (71.1)</td><td align="left" rowspan="1" colspan="1">0.40</td></tr><tr><td align="left" rowspan="1" colspan="1">Positive</td><td align="left" rowspan="1" colspan="1">12 (20.3)</td><td align="left" rowspan="1" colspan="1">47 (79.7)</td><td align="left" rowspan="1" colspan="1"/></tr></tbody></table><table-wrap-foot><fn id="nt102"><label>0</label><p>&#x003c7; Test</p></fn></table-wrap-foot></table-wrap></sec><sec id="s2d"><title>Impact of biopathological parameters on disease free survival</title><p>At a median follow up of 58 months (range 1&#x02013;179 months), a total of 36 patients (15&#x00025;) showed progressive disease.</p><p>The results of the univariate and multivariate analyses for DFS in the 232 patients included in this study are summarized in <xref ref-type="table" rid="pone-0001592-t003">Table 3</xref>. Univariate analysis (Cox model) identified tumor size (HR 2.42, C.I. 1.25&#x02013;4.68, p&#x0200a;&#x0003d;&#x0200a;0.009), grading (G3, HR 4.78, C.I. 1.05&#x02013;21.69, p&#x0200a;&#x0003d;&#x0200a;0.04), nodal status (HR 2.25, C.I. 1.15&#x02013;4.39, p&#x0200a;&#x0003d;&#x0200a;0.018), ErbB-3 (HR 3.01, C.I. 1.56&#x02013;5.82, p&#x0200a;&#x0003d;&#x0200a;0.001), P-Akt overexpression (HR 5.03, C.I. 1.90&#x02013;13.32, p&#x0200a;&#x0003d;&#x0200a;0.001) and lack of ER &#x003b2;1 (HR 3.88, C.I. 1.98&#x02013;7.59, p&#x0003c;0.0001) as significant predictors of DFS.</p><table-wrap id="pone-0001592-t003" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0001592.t003</object-id><label>Table 3</label><caption><title>Univariate and Multivariate analisyes of prognostic factors for Disease-Free Survival in 232 TAM treated breast cancer patients</title></caption><graphic id="pone-0001592-t003-3" xlink:href="pone.0001592.t003"/><table frame="hsides" rules="groups" alternate-form-of="pone-0001592-t003-3"><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup><thead><tr><td align="left" rowspan="1" colspan="1"/><td colspan="2" align="left" rowspan="1">Univariate analysis</td><td colspan="2" align="left" rowspan="1">Multivariate analysis</td></tr><tr><td align="left" rowspan="1" colspan="1">Factors</td><td align="left" rowspan="1" colspan="1">HR (95&#x00025; CI)</td><td align="left" rowspan="1" colspan="1">p value</td><td align="left" rowspan="1" colspan="1">HR (95&#x00025; CI)</td><td align="left" rowspan="1" colspan="1">p value</td></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1"><bold>Tumor size</bold></td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x0003e;2 cm <italic>vs</italic>&#x0003c;2 cm</td><td align="left" rowspan="1" colspan="1">2.42 (1.25&#x02013;4.68)</td><td align="left" rowspan="1" colspan="1"><bold>0.009</bold></td><td align="left" rowspan="1" colspan="1">2.24 (1.10&#x02013;4.53)</td><td align="left" rowspan="1" colspan="1"><bold>0.02</bold></td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Grading</bold></td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">G2 vs G1</td><td align="left" rowspan="1" colspan="1">3.19 (0.75&#x02013;13.59)</td><td align="left" rowspan="1" colspan="1">0.12</td><td align="left" rowspan="1" colspan="1">5.61 (1.25&#x02013;25.30)</td><td align="left" rowspan="1" colspan="1"><bold>0.02</bold></td></tr><tr><td align="left" rowspan="1" colspan="1">G3 vs G1</td><td align="left" rowspan="1" colspan="1">4.78 (1.05&#x02013;21.69)</td><td align="left" rowspan="1" colspan="1"><bold>0.04</bold></td><td align="left" rowspan="1" colspan="1">10.23 (2.07&#x02013;50.45)</td><td align="left" rowspan="1" colspan="1"><bold>0.004</bold></td></tr><tr><td align="left" rowspan="1" colspan="1">G2 <italic>vs</italic> G3</td><td align="left" rowspan="1" colspan="1">0.67 (0.33&#x02013;1.37)</td><td align="left" rowspan="1" colspan="1">0.27</td><td align="left" rowspan="1" colspan="1">0.55 (0.26&#x02013;1.17)</td><td align="left" rowspan="1" colspan="1">0.12</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Nodal status</bold></td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">N<sub>&#x0002b;</sub> vs N<sub>0</sub></td><td align="left" rowspan="1" colspan="1">2.25 (1.15&#x02013;4.39)</td><td align="left" rowspan="1" colspan="1"><bold>0.018</bold></td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">n.s.</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Integrin &#x003b2;<sub>4</sub></bold></td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">positive <italic>vs</italic> negative</td><td align="left" rowspan="1" colspan="1">1.37 (0.63&#x02013;2.95)</td><td align="left" rowspan="1" colspan="1">0.42</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">n.s.</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>ErbB-3</bold></td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">positive <italic>vs</italic> negative</td><td align="left" rowspan="1" colspan="1">3.01 (1.56&#x02013;5.82)</td><td align="left" rowspan="1" colspan="1"><bold>0.001</bold></td><td align="left" rowspan="1" colspan="1">2.16 (1.10&#x02013;4.22)</td><td align="left" rowspan="1" colspan="1"><bold>0.024</bold></td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>P-Akt (ser473)</bold></td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">positive <italic>vs</italic> negative</td><td align="left" rowspan="1" colspan="1">5.03 (1.90&#x02013;13.32)</td><td align="left" rowspan="1" colspan="1"><bold>0.001</bold></td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">n.s</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>ER&#x003b2;1</bold></td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">negative <italic>vs</italic> positive</td><td align="left" rowspan="1" colspan="1">3.88 (1.98&#x02013;7.59)</td><td align="left" rowspan="1" colspan="1"><bold>&#x0003c;0.0001</bold></td><td align="left" rowspan="1" colspan="1">3.28 (1.56&#x02013;6.87)</td><td align="left" rowspan="1" colspan="1"><bold>0.002</bold></td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>ErbB-2</bold></td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">positive <italic>vs</italic> negative</td><td align="left" rowspan="1" colspan="1">1.12 (0.55&#x02013;2.28)</td><td align="left" rowspan="1" colspan="1">0.75</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">n.s.</td></tr></tbody></table></table-wrap><p>Each variable that significantly affected DFS in the univariate analyses were introduced into a Cox proportional risk model. Multivariate analyses revealed that tumor size (HR 2.24, C.I. 1.10&#x02013;4.53, p&#x0200a;&#x0003d;&#x0200a;0.02), grading (G2 vs G1, HR 5.61, C.I. 1.25&#x02013;25.30, p&#x0200a;&#x0003d;&#x0200a;0.02 and G3 vs G1, HR 10.23, C.I. 2.07&#x02013;50.45, p&#x0200a;&#x0003d;&#x0200a;0.004), ErbB-3 expression (HR 2.16, C.I. 1.10&#x02013;4.22, p&#x0200a;&#x0003d;&#x0200a;0.024) and lack of ER&#x003b2;1 (HR 3.28, C.I. 1.56&#x02013;6.87, p&#x0200a;&#x0003d;&#x0200a;0.002) were independent prognostic variables influencing DFS. ER&#x003b2;1 negativity appears to be the most powerful prognostic indicator of a reduced DFS, indicating that ER&#x003b2;1 positive tumors are more likely to be responsive to TAM therapy.</p><p>Kaplan-Meier curves (<xref ref-type="fig" rid="pone-0001592-g005">Figure 5</xref>), stratified, respectively, for &#x003b2;4, ErbB-3, P-Akt and ER&#x003b2;1 expression in all valuable cases, indicate that a significantly longer DFS can be observed in patients with ErbB-3 negative (p&#x0200a;&#x0003d;&#x0200a;0.0006), P-Akt negative (p&#x0200a;&#x0003d;&#x0200a;0.005) and ER&#x003b2;1 positive (p&#x0003c;0.0001) tumors. &#x003b2;4 expression, considered as a single factor, did not influence the patient outcome.</p><fig id="pone-0001592-g005" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0001592.g005</object-id><label>Figure 5</label><caption><title>DFS (232 cases) for TAM treated patients with BC categorised on the basis of (A) &#x003b2;4, (B) ErbB-3, (C) P-Akt (ser473), (D) ER&#x003b2;1 expression.</title><p>Survival curves were generated according to the Kaplan-Meier method; statistical comparisons were made using the log-rank test.</p></caption><graphic xlink:href="pone.0001592.g005"/></fig><p>On the basis of these results, we evaluated the impact on DFS of &#x003b2;4, ErbB-3, P-Akt and ER&#x003b2;1 combination. &#x003b2;4 expression, even if associated to the other three variables, did not add further useful clinical information. In contrast, as shown in <xref ref-type="fig" rid="pone-0001592-g006">Figure 6</xref>, the results obtained provide statistically significant evidence which indicates that the association of ErbB-3 positivity with ER&#x003b2;1 negativity (p&#x0003c;0.0001) as well as the concomitant overexpression of p-Akt and ErbB3 (p&#x0200a;&#x0003d;&#x0200a;0.0005) can identify subsets of patients with a high probability of relapsing within five years due to a worse response to TAM therapy.</p><fig id="pone-0001592-g006" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0001592.g006</object-id><label>Figure 6</label><caption><title>DFS (232 cases) for TAM treated patients with breast carcinomas categorised according to the combinations in all evaluated cases of (A) ErbB-3 and ER&#x003b2;1 expression, (B) ErbB-3 and P-Akt expression.</title><p>Survival curves were generated according to the Kaplan-Meier method; statistical comparisons were made using the log-rank test.</p></caption><graphic xlink:href="pone.0001592.g006"/></fig></sec></sec><sec id="s3"><title>Discussion</title><p>It is widely known that &#x003b1;6&#x003b2;4 integrin expression and signaling are involved in the mechanisms that regulate tumor progression and resistance to apoptotic stimuli <xref ref-type="bibr" rid="pone.0001592-Shaw1">&#x0005b;4&#x0005d;</xref>&#x02013;<xref ref-type="bibr" rid="pone.0001592-Bachelder1">&#x0005b;9&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0001592-Lipscomb2">&#x0005b;13&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0001592-Folgiero1">&#x0005b;15&#x0005d;</xref>. One of these mechanisms involves the ability of &#x003b1;6&#x003b2;4 integrin to regulate the translation of ErbB-3 receptor in a manner which is eIF-4E-dependent <xref ref-type="bibr" rid="pone.0001592-Folgiero1">&#x0005b;15&#x0005d;</xref>. The ErbB-3 up-regulation associated with &#x003b1;6&#x003b2;4 integrin over-expression results in an increase of ErbB-2/ErbB-3 heterodimerization and consequent Akt phosphorylation favoring the survival of BC cells <xref ref-type="bibr" rid="pone.0001592-Folgiero1">&#x0005b;15&#x0005d;</xref>. In the present work, we extended our previous study <xref ref-type="bibr" rid="pone.0001592-Folgiero1">&#x0005b;15&#x0005d;</xref> to a novel panel of human BC cell lines which express different levels of &#x003b1;6&#x003b2;4 integrin confirming that the integrin expression correlates with ErbB-3 protein positivity. We also showed that &#x003b2;4 integrin depletion inhibits ErbB-3 translation and strongly reduces Akt activity while, ErbB-3 depletion abrogates Akt phosphorylation. Furthermore, the involvement of ErbB-3 in tumor progression was also supported by the finding that its depletion, in the absence of hormone stimuli, induces apoptosis, inhibits the <italic>in vitro</italic> invasion and favors TAM responsiveness. Given that ErbB-3 protein binds the regulatory subunit of PI3K but lacks kinase activity <xref ref-type="bibr" rid="pone.0001592-Hellyer1">&#x0005b;24&#x0005d;</xref>, our observations imply that ErbB-2/ErbB-3 sustains the survival of BC cells in the absence of ERs signaling through the activation of PI3K pathway. This hypothesis is strongly supported by recent findings which demonstrate that ErbB3 down-regulation by RNA interference abrogates ErbB-2-mediated TAM resistance in BC cells <xref ref-type="bibr" rid="pone.0001592-Liu1">&#x0005b;25&#x0005d;</xref>.</p><p>Our results are of particular clinical interest, since the anti-estrogen TAM plays a central role in the treatment of human BC. Nevertheless, many tumors appear to be refractory to TAM, making it necessary to discover predictive markers that can accurately identify hormone responsive tumors. In this setting, till the discovery of ER&#x003b2;, ER&#x003b1; was the single most informative marker, receptor-negative tumors rarely benefiting from endocrine therapy <xref ref-type="bibr" rid="pone.0001592-Miller1">&#x0005b;26&#x0005d;</xref>&#x02013;<xref ref-type="bibr" rid="pone.0001592-Miller2">&#x0005b;27&#x0005d;</xref>. In particular, it is important to note that cell-based studies have suggested that coexpression of ER&#x003b2; in ER&#x003b1;-positive cells may modulate the ability of the cells to respond to estrogens <xref ref-type="bibr" rid="pone.0001592-Strom1">&#x0005b;28&#x0005d;</xref>&#x02013;<xref ref-type="bibr" rid="pone.0001592-Barnes1">&#x0005b;29&#x0005d;</xref> and studies using mice with targeted disruption of the ER&#x003b2; gene have further supported this idea <xref ref-type="bibr" rid="pone.0001592-Lindberg1">&#x0005b;30&#x0005d;</xref>. There is considerable evidence suggesting that for each action to block estrogen stimulation of BC cells, there are different reactions that tumor cells can adopt to escape the attempts to block their growth <xref ref-type="bibr" rid="pone.0001592-Nicholson1">&#x0005b;31&#x0005d;</xref>. The activation of growth factor signaling is involved in the mechanism of resistance to endocrine therapy and it has been hypothesized that it may substitute estrogen in sustaining the growth and survival of BC cells <xref ref-type="bibr" rid="pone.0001592-Nicholson1">&#x0005b;31&#x0005d;</xref>.</p><p>Aimed at translating our in vitro results to human BC, we evaluated, by IHC, &#x003b1;6&#x003b2;4, ER&#x003b2;1, ErbB3, and P-AKT expression in 232 primary mammary tumors derived from patients submitted to adjuvant TAM monotherapy. Even though we found a significant correlation between &#x003b2;4 and ErbB-3 expression and ER&#x003b2;1 negativity, in the BCs we analyzed, the expression of the integrin did not influence the patient outcome.</p><p>ErbB-3 proteins mainly occurred in the P-Akt-positive and ER&#x003b2;1-negative BC derived from patients with lower DFS. Although previous experimental studies have implied that &#x003b1;6&#x003b2;4 integrin facilitates tumor progression by regulating growth factor receptors signaling <xref ref-type="bibr" rid="pone.0001592-Folgiero1">&#x0005b;15&#x0005d;</xref>, to our knowledge this is the first study demonstrating an i<italic>n vivo</italic> correlation between &#x003b2;4 and ErbB-3 expression suggesting that &#x003b2;4 can regulate ErbB-3 protein <italic>in vivo</italic> and favor indirectly tumor progression.</p><p>The high percentage of mammary tumors we analyzed which over-express &#x003b2;4 integrin subunit is consistent with previous findings <xref ref-type="bibr" rid="pone.0001592-Bon1">&#x0005b;8&#x0005d;</xref>. Although <italic>in vivo</italic> &#x003b1;6&#x003b2;4 integrin expression has not been extensively evaluated, there are two separate studies reporting that 90&#x00025; of advanced BC expressed &#x003b1;6 subunit <xref ref-type="bibr" rid="pone.0001592-Friedrichs1">&#x0005b;32&#x0005d;</xref> and that high level of &#x003b1;6&#x003b2;4 expression in mammary tumor has prognostic value <xref ref-type="bibr" rid="pone.0001592-Tagliabue1">&#x0005b;33&#x0005d;</xref>. Furthermore, the over-expression of &#x003b2;4 integrin subunit in the ER&#x003b2;1-negative tumors we have analyzed is also in agreement with a recent study which demonstrates that laminin-binding integrins and especially &#x003b2;4 integrin subunit is elevated in ER-negative BC <xref ref-type="bibr" rid="pone.0001592-Perou1">&#x0005b;34&#x0005d;</xref>.</p><p>These and numerous other studies conducted <italic>in vivo</italic> in a smaller number of tumors clearly indicate that &#x003b2;4 molecule mediates the signaling events which play a role in tumor progression <xref ref-type="bibr" rid="pone.0001592-Bon1">&#x0005b;8&#x0005d;</xref>. This hypothesis is based on the capability of this integrin to enhance not only the translation of growth factor receptor but also of key growth factor such as VEGF <xref ref-type="bibr" rid="pone.0001592-Lipscomb2">&#x0005b;13&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0001592-Chung1">&#x0005b;35&#x0005d;</xref>. It has been observed that ablation of &#x003b1;6&#x003b2;4 expression by shRNA in BC cells impaired the ability of these cells to form xenograft tumors and to produce VEGF <xref ref-type="bibr" rid="pone.0001592-Lipscomb2">&#x0005b;13&#x0005d;</xref>. Moreover, the finding that the depletion of &#x003b1;6&#x003b2;4 integrin in mammary cells inhibits the PI3K pathway and facilitates the responsiveness to TAM treatment <xref ref-type="bibr" rid="pone.0001592-Bon2">&#x0005b;12&#x0005d;</xref> correlates with the capability of &#x003b1;6&#x003b2;4 integrin to regulate ErbB-3 translation and subsequent Akt activation <xref ref-type="bibr" rid="pone.0001592-Folgiero1">&#x0005b;15&#x0005d;</xref>. We can hypothesize that &#x003b1;6&#x003b2;4 integrin controls the translation of key molecules whose functions are strictly related to carcinoma survival. The ability of &#x003b1;6&#x003b2;4 integrin to control ErbB-3 expression <italic>in vitro</italic><xref ref-type="bibr" rid="pone.0001592-Folgiero1">&#x0005b;15&#x0005d;</xref> and the strong relationship between &#x003b2;4 and ErbB-3 receptor (P&#x0200a;&#x0003d;&#x0200a;0.003, see <xref ref-type="table" rid="pone-0001592-t002">Table 2</xref>) we observed <italic>in vivo</italic> confirms this hypothesis. Although in the BC we analyzed, &#x003b2;4 does not directly influence the patient outcome, its expression may influence a different regulation of ErbB-3 and consequently, as suggested by our analyses, PI3K activation through its heterodimerization with ErbB-2. Collectively, these phenotypic alterations may have a significant impact on DFS.</p><p>From our data it is evident that ErbB-3 may represent a key molecule involved in the mechanisms of TAM resistance in ER&#x003b2;1-negative BC. This finding is in agreement with a recent report demonstrating that ErbB-3 modulates ErbB-2-mediated proliferation, colony formation and resistance to TAM treatment <xref ref-type="bibr" rid="pone.0001592-Liu1">&#x0005b;25&#x0005d;</xref>. Even though there are many studies on the role of ErbB-2 in BC prognosis and therapeutic response, little is known regarding the role of ErbB-3 protein in these processes <xref ref-type="bibr" rid="pone.0001592-Osborne1">&#x0005b;18&#x0005d;</xref>. However, in agreement with our data, it has been found that the DFS is shorter in patients with ErbB-3 overexpression and that the level of ErbB-3 expression in primary BC seems to be involved in tumor progression from non-invasive to invasive tumors <xref ref-type="bibr" rid="pone.0001592-Naidu1">&#x0005b;36&#x0005d;</xref>. Moreover, it has also been shown that ErbB1-3 positive tumors had significantly poorer survival <xref ref-type="bibr" rid="pone.0001592-Witton1">&#x0005b;37&#x0005d;</xref>. The strong relationship we found between ErbB-3 and P-Akt positivity and low DFS relative to patients with ER&#x003b2;1-negativity reinforces the hypothesis that growth factor signaling is involved in the mechanism of resistance to endocrine therapy. However, from our study, it is clear that ER&#x003b2;1 negativity appears to be the most powerful prognostic factor influencing DFS in response to TAM treatment and this data is in agreement with previous observations showing that low level of ER&#x003b2; predict resistance to TAM treatment <xref ref-type="bibr" rid="pone.0001592-Hopp1">&#x0005b;38&#x0005d;</xref>. Together these studies provide strong evidence that ER&#x003b2;1 is a predictor of response to TAM treatment in BC.</p><p>We can conclude that, even though the regulation of mammary tumor growth and survival by ERs and EGFR family members and the biology of &#x003b2;4 integrin in tumors are not completely known, our <italic>in vitro</italic> and <italic>in vivo</italic> results provide strong evidence of a functional cooperation among these factors in supporting the survival of mammary tumors and this cooperation in ER&#x003b2;1-negative tumors may result in a decreased responsiveness to TAM therapy.</p></sec><sec sec-type="materials|methods" id="s4"><title>Materials and Methods</title><sec id="s4a"><title>Cell lines</title><p>The human mammary carcinoma cell lines, MDA-MB361, BT474, SKBr3, MDA-MB231, T47D and BT549 were obtained from the ATCC and maintained in DMEM medium supplemented with 10&#x00025; FCS (INVITROGEN, Milan, Italy). Rat bladder epithelial cell line 804G was cultured in minimum essential medium supplemented with 10&#x00025; FCS and employed for LM5 rich matrix preparation <xref ref-type="bibr" rid="pone.0001592-Langhofer1">&#x0005b;39&#x0005d;</xref>.</p></sec><sec id="s4b"><title>Antibody and matrix proteins</title><p>The rat anti-hum &#x003b2;4 subunit (Clone 439-9B) was prepared as previously described and used in immunoprecipitation, and immunofluorescence (FACS) analysis experiments <xref ref-type="bibr" rid="pone.0001592-Gambaletta1">&#x0005b;6&#x0005d;</xref>. The mouse anti-human &#x003b2;4 subunit 450-11A was used in western blotting and immunohistochemistry experiments <xref ref-type="bibr" rid="pone.0001592-Bon2">&#x0005b;12&#x0005d;</xref>. The rabbit anti-ErbB-3 &#x0005b;Ab (C17), Ab6 (2B5)&#x0005d; and the mouse anti-ErbB-3 Ab (Ab-4 Clone H3.90.6) were used in western blot, immunoprecipitation and in immunofluorescence (FACS) analysis experiments, respectively. Clones C17 and 2B5 were purchased from Santa Cruz Biotechnologioes (Milan, IT) and clone Ab4 was purchased from NeoMarkers (Fremont, CA). The rabbit anti total and phospho-AKT (Ser473) antibodies were purchased from Cell Signaling (Milan, IT). The rabbit anti ER&#x003b1; and the mouse anti ER&#x003b2; Abs were purchased from Santa Cruz Biotechnologioes (Milan, IT) and UCS Diagnostic (Rome, IT) respectively. The hsp70 (N27F3-4) Ab was purchased from Stressgen (Milan, IT). The mouse anti-PARP (Clone C2-10) was purchased from Pharmingen (Milan, Italy). FITC and Peroxidase-conjugated anti-IgGs were purchased from Cappel and BioRad (Milan, IT).The laminin-5-rich matrix from 804G cells was prepared as described previously <xref ref-type="bibr" rid="pone.0001592-Langhofer1">&#x0005b;39&#x0005d;</xref>. In brief, 804G cells were plated onto 100 mm dishes or 96 well plates and allowed to reach confluence. The cells were washed in sterile PBS and were removed from their matrix by treatment for 10 min in 20 mM NH<sub>4</sub>OH at 4&#x000b0;C. The remaining cells were removed by washing three times with sterile PBS. The Poly-L-lysine was from SIGMA (Milan, Italy).</p></sec><sec id="s4c"><title>Flow cytometry analysis</title><p>The expression level of &#x003b2;4, ErbB2 and ErbB-3 in MDA-MB 231, MDA-MB 361, BT474, SKBr3, BT549 and T47D cells was detected by flow cytometry analysis of stained cells. In brief, cells harvested using citrate saline buffer (0.134 M KCl, 0.015 M Na citrate) were washed twice with cold PBS containing 0.002&#x00025; EDTA and 10 mM NaN<sub>3</sub> (washing buffer). Samples of 1&#x000d7;10<sup>6</sup> cells were incubated for 1 h at 4&#x000b0;C with saturating concentrations of primary antibodies diluted in PBS containing 0.5&#x00025; bovine serum albumin (BSA). Cells were then washed three times with washing buffer (PBS containing 0.5&#x00025; BSA) and incubated for 1 h at 4&#x000b0;C with 50 l of FITC-conjugated secondary antibodies &#x0005b;F(ab')2 (Cappel, West Chester, PA, U.S.A.)&#x0005d; diluted 1:20 in PBS/BSA. After three washes, the cells were suspended in 1 ml of washing buffer. Cell suspensions were analyzed by a flow-cytometer (Epics XL analyzer, Coulter Corporation, Miami, FL) after addition of 5l of a 1mg/ml solution of propidium iodide to exclude non-viable cells. At least 1&#x000d7;10<sup>4</sup> cells per sample were analyzed.</p></sec><sec id="s4d"><title>Western Blot analysis</title><p>To analyze ER-&#x003b1;, &#x003b2;4 and ErbB-3 protein expression, the cells were lysed with RIPA buffer (50 mM Tris (pH 8), 150 mM NaCl, 1&#x00025; Nonidet P40, 0,1&#x00025; deoxycholate, 0,1&#x00025; SDS, 1mM PMSF, 5 mM Na<sub>3</sub>VO<sub>4</sub>, 50 mM protease inhibitors (SIGMA-Aldrich, Milan, IT) for 30 minutes at 4&#x000b0;C. Total cell lysates were clarified by centrifugation at 14,000 rpm for 30 minutes. Aliquots of cell extracts containing an equivalent amount of proteins were resolved by SDS-polyacrilamide gel electrophoresis 10&#x00025; (SDS-PAGE) and transferred to nitrocellulose. To analyze Akt activation after stimulation by LM5, MDA-MB 361, BT474 and SKBr3 (1&#x000d7;10<sup>6</sup>) cell lines, after serum starvation for 24 hours, were seeded onto 100 mm tissue culture dishes coated with LM5-rich matrix preparation from 804G cells. The cells were washed three times with ice cold PBS and lysed with NP40 buffer (1&#x00025; Nonidet P40, 10&#x00025; glycerol, 137 mM NaCl, 20 mM Tris HCl (pH 7,4), 50 mM NaF, 1 mM PMSF, 5mM Na<sub>3</sub>VO<sub>4, </sub>50 mM protease inhibitors (SIGMA-Aldrich, Milan, IT) for 30 minutes at 4&#x000b0;C. Total cell lysates were clarified by centrifugation at 14,000 rpm for 30 minutes. Aliquots of cell extracts containing equivalent amounts of proteins were resolved by SDS-PAGE, transferred to nitrocellulose and probed with the rabbit polyclonal Ab directs to P-Akt. As secondary Abs, the horseradish peroxidase-coniugated goat anti-mouse or rabbit were used. The chemiluminescence was resolved by an enhanced chemiluminescence ECL kit (Amersham, Milan, IT). Total proteins were normalized by anti-actin, anti-Hsp70 and total-Akt Abs, respectively.</p></sec><sec id="s4e"><title>RT-PCR</title><p>Total RNA was prepared using RNAzol B according to the manufacturer's procedure (Invitrogen, Milan, IT). Human ER&#x003b2;1 mRNA for RT-PCR analysis was carried out using specific primers as previously described <xref ref-type="bibr" rid="pone.0001592-CampbellThompson1">&#x0005b;40&#x0005d;</xref>. The oligonucleotides we use to amplify ER&#x003b2;1 mRNA were as follow:</p><list list-type="order"><list-item><p>hERb1 sense: <named-content content-type="gene">5&#x02032;TGCTTTGGTTTGGGTGATTGC3&#x02032;;</named-content></p></list-item><list-item><p>hER&#x003b2;1 anti-sense: <named-content content-type="gene">5&#x02032;TTTGCTTTTACTGTCCTCTGC3&#x02032;</named-content>.</p></list-item></list><p>The housekeeping aldolase mRNA was used as an internal control.</p></sec><sec id="s4f"><title>Immunocytochemistry</title><p>For the detection of ER&#x003b2; by immunocytochemistry, 5&#x000d7;10<sup>5</sup> cells of each cell line (MDA-MB 231, MDA-MB 361, SKBr3, BT474, BT549 and T47D) were centrifuged onto glass slides (cytospin) and fixed in 2&#x00025; formaldehyde for 10 minutes. Endogenous peroxidase was blocked by incubating in 3&#x00025; H<sub>2</sub>O<sub>2</sub> in PBS for 10 minutes. After two rinses in PBS, nonspecific binding was blocked by a 10-minute incubation with normal serum (ScyTek Laboratories, Logan, UT). Samples were then incubated in mouse anti-ER&#x003b2;1 antibody (1&#x02236;20 dilution) in 0,5&#x00025; bovine serum albumine with PBS overnight, in a humidified atmosphere. Detection steps were done using the UltraTek HRP kit according to the manufacturer's procedure (ScyTek Laboratories), and peroxidase activity was localized with DAB (diamino-benzidine) substrate. Slides were counterstained by Hematoxilin and mounted under a coverslip in glycerol.</p></sec><sec id="s4g"><title>RNA Interference</title><p>The inactivation of &#x003b2;4 was obtained by the LipofectAMINE PLUS&#x02122; method (INVITROGEN) using pSUPER.retro vector containing &#x003b2;4-shRNA or scramble RNA (scr-shRNA) sequences. To inactivate ErbB-3 expression, cells were transiently transfected with Transit-TKO reagent (MIRUS, Medison, Wisconsin) following the manufacturer procedures with the ErbB-3 anti-sense double strand siRNA as previously described <xref ref-type="bibr" rid="pone.0001592-Folgiero1">&#x0005b;15&#x0005d;</xref>. The cells were harvested 48 hours post transfection with RIPA buffer for the detection of &#x003b2;4 and ErbB3 expression and with NP-40 buffer for the detection of P-AKT. Total proteins were separated by 8&#x00025; and 10&#x00025; SDS-PAGE respectively and transferred to nitrocellulose. The proteins were detected by western blot analysis as described above.</p></sec><sec id="s4h"><title>Cell death and apoptosis</title><p>SKBr3, MDA-MB 361, BT474, TD47D and MDA-MB 231 cells (3&#x000d7;10<sup>5</sup>) were plated onto 60mm dishes in hormone-deprivation conditions for three days. The following day, the cells were trasiently transfected with a scrambled or ErbB-3 siRNA sequence and 24 hours after transfection the cells were treated with 2.5 &#x000b5;M TAM or ethanol as a control for 24 hrs. The viability of the cells was evaluated by Trypan blue exclusion. Each assay was repeated at least three times. Following the same procedure, the cells were lysed in Triton buffer (20 mM Tris pH 7.5, 150 mM NaCl, 1 mM EDTA, 1 mM EGTA, 1&#x00025; Triton x-100, 0.5&#x00025; NP40, 2.5&#x00025; sodium pyrophosphatate, 1 mM Na<sub>3</sub>VO<sub>4</sub>, 50 mM protease inhibitors) and sonicated for 15 seconds. Samples were boiled for 5 minutes at 95&#x000b0;C, resolved by SDS-polyacrilamide gel electrophoresis (8&#x00025;), transferred to nitrocellulose and probed with a mouse anti-PARP Ab.</p></sec><sec id="s4i"><title>Chemoinvasion assay</title><p>Chemoinvasion was assessed using a 48-well modified Boyden's chamber (NeuroProbe, Pleasanton, CA) and 8-&#x000b5;m pore polyvinyl pyrrolidone&#x02013;free polycarbonate Nucleopore filters (Costar, New York, NY). The filters were coated with an even layer of 3 mg/mL Cultrex (Trevigen, Gaithersburg, MD). The lower compartment of the chamber was filled with 24 hours conditioned serum free medium produced from NIH3T3 fibroblasts. SKBr3, MDA MB361, BT474, TD47D and MDA-MB 231 cells, after 3 days of hormone deprivation, were plated (1.5&#x000d7;10<sup>6</sup> cells) onto 100 mm dishes. The following day, the cells were transfected with scrambled or ErbB-3 siRNA. Where specified, 24 hrs after transfection scrambled and ErbB-3 interferred cells were pre-incubated for 24 hours at 37&#x000b0;C with TAM 2.5 &#x000b5;M. The cells were, then, harvested (2&#x000d7;10<sup>6</sup> cells/ml) and placed in the upper compartment (45 &#x000b5;l/well) of the Boyden's chamber. After 8 hours of incubation at 37&#x000b0;C, the cells migrated on the lower surface of the filters were fixed and stained with DiffQuick (Merz-Dade, Dudingen, Switzerland). Then, the migrated cells in 12 high-power fields were counted. Each assay was carried out in quadruplicate and repeated at least three times. The ability of the cells to adhere to the filters was verified by staining the upper side of the filter for each cell line.</p></sec><sec id="s4j"><title>Patients</title><p>We studied a cohort of 232 hormonal receptor positive breast cancer patients surgically treated at the Regina Elena Cancer Institute (Rome, Italy) between 1986 and 2002, who had received an up-front adjuvant hormonal monotherapy with TAM at the dose of 20 mg per day for a maximum of 5 years. Invasive breast cancers were classified according to the World Health Organization Classification of Tumors <xref ref-type="bibr" rid="pone.0001592-Travasoli1">&#x0005b;41&#x0005d;</xref> and were graded according to Bloom and Richardson. The information recorded for each patient consisted of: age at surgery, menopausal status, tumor size, axillary node status, histotype, and histologic grade. Patients selected for the study presented complete follow-up data and uniform methodology for hormone receptor content determination.</p><p>The study was reviewed and approved by the ethical committee of Regina Elena National Cancer Institute, and written informed consent was obtained from all patients.</p></sec><sec id="s4k"><title>Immunohistochemistry</title><p>&#x003b2;4 integrin, ER&#x003b2;1, P-AKT(ser473), ErbB-2 and ErbB-3 expression were assessed by indirect immunoperoxidase staining. Immunohistochemical staining was carried out on 5-&#x000b5;m-thick paraffin-embedded tissues. Sections were harvested on SuperFrost Plus slides (Menzel-Glaser, Braunschweig, Germany).</p><p>The deparaffinized and rehydrated sections were pretreated by microwave in 1mM citrate buffer (pH6.0) at 430 W (two 10&#x02032; cycles followed by a 5&#x02032; one) for ER&#x003b2;1 and at 760 W (three 5&#x02032; cycles) for p-AKT(ser473), ErbB-2, ErbB-3 and &#x003b2;4 antigen.</p><p>Sections were incubated overnight with the anti-ER&#x003b2;1 (clone PPG5/10, Biogenex,Space, Milan, Italy), the anti-&#x003b2;4 integrin (clone 450-11A directed to the cytoplasmic tail of the subunit) <xref ref-type="bibr" rid="pone.0001592-Bon2">&#x0005b;12&#x0005d;</xref>, the anti p-AKT(ser473) (Cell Signaling Technology, Sial, Rome, IT) and the anti-c-ErbB-3 (ErbB-3, clone RTJ-1, Novocastra Menarini, Florence, IT). ER&#x003b2;1 was considered positive when more than 20&#x00025; of neoplastic cells showed a nuclear immunoreactivity. ErbB-2 and ErbB-3 overexpression was determined as defined in the HercepTest kit guide (0 or 1&#x0002b; negative, 2&#x0002b; and 3&#x0002b; positive).</p><p>The integrin &#x003b2;4 subunit was evidenced both in the membrane and in the cytoplasm of neoplastic cells and was scored considering both intensity and frequency from 0 to 2 according to the following criteria: 0. No Reaction, 1. Low Reaction (1&#x02013;10&#x00025; of positive cells with score &#x0002b;/&#x0002b;&#x0002b;/&#x0002b;&#x0002b;&#x0002b; or &#x0003e;10&#x02013;50&#x00025; with score &#x0002b;), 2. High Reaction (&#x0003e;10&#x02013;50&#x00025; of positive cells with score &#x0002b;&#x0002b;/&#x0002b;&#x0002b;&#x0002b; or &#x0003e;50&#x00025; with score &#x0002b;/&#x0002b;&#x0002b;/&#x0002b;&#x0002b;&#x0002b;). The P-AKT(ser473) immunostaining was scored as described for &#x003b2;4 protein.</p><p>The immunoreactions were revealed by a streptavidin-biotin-peroxidase system (Super Sensitive Link-Label IHC Detection System, Biogenex) using 3-amino-9-ethylcarbazole (Dako, Milan, IT) as a chromogenic substrate. All sections were slightly counterstained with Mayer's hematoxylin and mounted in aqueous mounting medium (UCS Diagnostics, Rome, IT). Evaluation of the immunohistochemical results was done independently and in blinded manner by two investigators (M.M, and P.A.).</p></sec><sec id="s4l"><title>Statistical analysis</title><p>The correlation between &#x003b2;4 integrin expression and the biopathological characteristic variables was tested by the Pearson Chi-Square test. For the purpose of our study, disease-free survival (DFS) was considered as a measure of poor outcome. The disease free survival was calculated from the date of tumor diagnosis to the date of first recurrence or metastasis. Patients without recurrence were censored at the time of last follow-up or death. The Hazard risk and the confidence limits were estimated for each variable using the Cox univariate model and adopting the most suitable prognostic category as the referent group. The DFS curves were estimated by the Kaplan-Meier product-limit method. The log-rank test was used to assess differences between subgroups, and significance was defined as p&#x0003c;0.05.</p><p>A multivariate Cox proportional hazard model was also developed using stepwise regression (forward selection) with predictive variables which were significant in the univariate analyses. The enter limit and remove limit were p&#x0200a;&#x0003d;&#x0200a;0.10 and p&#x0200a;&#x0003d;&#x0200a;0.15, respectively. The SPSS (11.0) statistical program was used for analysis.</p></sec></sec><sec sec-type="supplementary-material" id="s5"><title>Supporting Information</title><supplementary-material content-type="local-data" id="pone.0001592.s001"><label>Figure S1</label><caption><p>The expression of ERbeta1 protein was evaluated by immunocytochemistry. 5&#x000d7;105 MDA-MB 231, MDA-MB 361, SKBr3, BT474, BT549 and T47D cells were centrifuged onto glass slides and fixed in 2&#x00025; formaldehyde for the dectection of ERb1 expression.</p><p>(10.39 MB TIF)</p></caption><media xlink:href="pone.0001592.s001.tif" mimetype="image" mime-subtype="tiff"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pone.0001592.s002"><label>Figure S2</label><caption><p>Representative invading stained cells. Chemoinvasion was assessed using a 48-well modified Boyden's chamber and 8-&#x003bc;m pore polyvinyl pyrrolidone-free polycarbonate filters. SKBr3, MDA MB361, BT474, TD47D and MDA-MB 231 (src, scr/TAM, B3si, B3si/TAM) cells migrated on the lower surface of the filters were fixed and stained. Then, the migrated cells in 12 high-power fields were counted. Each assay was carried out in quadruplicate and repeated at least three times.</p><p>(10.34 MB TIF)</p></caption><media xlink:href="pone.0001592.s002.tif" mimetype="image" mime-subtype="tiff"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material></sec></body><back><ack><p>We would like to thank Silvia Soddu for helpful discussions and critical reading of the manuscript, Simona Nanni for helpful discussion in ERs field. Maria Pia Gentileschi for technical assistance, Maria Assunta Fonsi for the secretarial assistance and Michael Kenyon for his formal revision of the manuscript.</p></ack><ref-list><title>References</title><ref id="pone.0001592-Hynes1"><label>1</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hynes</surname><given-names>NE</given-names></name><name><surname>Lane</surname><given-names>HA</given-names></name></person-group><year>2005</year><article-title>ERBB receptors and cancer: the complexity of targeted inhibitors.</article-title><source>Nat Rev Cancer</source><volume>5</volume><fpage>341</fpage><lpage>354</lpage><pub-id pub-id-type="pmid">15864276</pub-id></citation></ref><ref id="pone.0001592-Yarden1"><label>2</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Yarden</surname><given-names>Y</given-names></name><name><surname>Sliwkowski</surname><given-names>MX</given-names></name></person-group><year>2001</year><article-title>Untangling the ErbB signaling network.</article-title><source>Nat. Rev Mol Cell Biol</source><volume>2</volume><fpage>127</fpage><lpage>137</lpage><pub-id pub-id-type="pmid">11252954</pub-id></citation></ref><ref id="pone.0001592-Harrari1"><label>3</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Harrari</surname><given-names>D</given-names></name><name><surname>Yarden</surname><given-names>Y</given-names></name></person-group><year>2000</year><article-title>Molecular Mechanisms underlying ErbB2/HER2 action in breast cancer.</article-title><source>Oncogene</source><volume>19</volume><fpage>6102</fpage><lpage>6114</lpage><pub-id pub-id-type="pmid">11156523</pub-id></citation></ref><ref id="pone.0001592-Shaw1"><label>4</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Shaw</surname><given-names>LM</given-names></name><name><surname>Rabinovitz</surname><given-names>I</given-names></name><name><surname>Wang</surname><given-names>HH</given-names></name><name><surname>Toker</surname><given-names>A</given-names></name><name><surname>Mercurio</surname><given-names>AM</given-names></name></person-group><year>1997</year><article-title>Activation of phosphoinositide 3-OH kinase by the &#x003b1;6&#x003b2;4 integrin promotes carcinoma invasion.</article-title><source>Cell</source><volume>91</volume><fpage>949</fpage><lpage>960</lpage><pub-id pub-id-type="pmid">9428518</pub-id></citation></ref><ref id="pone.0001592-Shaw2"><label>5</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Shaw</surname><given-names>LM</given-names></name></person-group><year>2001</year><article-title>Identification of insulin receptor substrate 1 (IRS-1) and IRS-2 as signaling intermediates in the alphbeta4 integrin-dependent activation of phosphoinositide 3-OH kinase and promotion of invasion.</article-title><source>Mol Cell Biol</source><volume>21</volume><fpage>5082</fpage><lpage>5093</lpage><pub-id pub-id-type="pmid">11438664</pub-id></citation></ref><ref id="pone.0001592-Gambaletta1"><label>6</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gambaletta</surname><given-names>D</given-names></name><name><surname>Marchetti</surname><given-names>A</given-names></name><name><surname>Benedetti</surname><given-names>L</given-names></name><name><surname>Mercurio</surname><given-names>AM</given-names></name><name><surname>Sacchi</surname><given-names>A</given-names></name><etal/></person-group><year>2000</year><article-title>Cooperative signaling between alpha(6)beta(4) integrin and ErbB-2 receptor is required to promote phosphatidylinositol 3-kinase-dependent invasion.</article-title><source>J Biol Chem</source><volume>275</volume><fpage>10604</fpage><lpage>10610</lpage><pub-id pub-id-type="pmid">10744756</pub-id></citation></ref><ref id="pone.0001592-Lipscomb1"><label>7</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lipscomb</surname><given-names>EA</given-names></name><name><surname>Mercurio</surname><given-names>AM</given-names></name></person-group><year>2005</year><article-title>Mobilization and activation of a signaling competent &#x003b1;6&#x003b2;4 integrin underlines its contribution to carcinoma progression.</article-title><source>Cancer and Metastasis Rev</source><volume>24</volume><fpage>413</fpage><lpage>423</lpage><pub-id pub-id-type="pmid">16258729</pub-id></citation></ref><ref id="pone.0001592-Bon1"><label>8</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bon</surname><given-names>G</given-names></name><name><surname>Folgiero</surname><given-names>V</given-names></name><name><surname>Di Carlo</surname><given-names>S</given-names></name><name><surname>Sacchi</surname><given-names>A</given-names></name><name><surname>Falcioni</surname><given-names>R</given-names></name></person-group><year>2007</year><article-title>The involvement of &#x003b1;6&#x003b2;4 integrin in the mechanisms that regulate Breast Cancer Progression.</article-title><source>Breast Cancer Res</source><volume>9</volume><fpage>1</fpage><lpage>5</lpage></citation></ref><ref id="pone.0001592-Bachelder1"><label>9</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bachelder</surname><given-names>RE</given-names></name><name><surname>Ribick</surname><given-names>MJ</given-names></name><name><surname>Marchetti</surname><given-names>A</given-names></name><name><surname>Falcioni</surname><given-names>R</given-names></name><name><surname>Soddu</surname><given-names>S</given-names></name><etal/></person-group><year>1999</year><article-title>p53 inhibits &#x003b1;6&#x003b2;4 integrin survival signaling by promoting the caspase 3-dependent cleavage of AKT/PKB.</article-title><source>J Cell Biol</source><volume>147</volume><fpage>1063</fpage><lpage>1072</lpage><pub-id pub-id-type="pmid">10579725</pub-id></citation></ref><ref id="pone.0001592-Falcioni1"><label>10</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Falcioni</surname><given-names>R</given-names></name><name><surname>Antonimi</surname><given-names>A</given-names></name><name><surname>Nistic&#x000f2;</surname><given-names>P</given-names></name><name><surname>Di Stefano</surname><given-names>S</given-names></name><name><surname>Crescenzi</surname><given-names>M</given-names></name><etal/></person-group><year>1997</year><article-title>&#x003b1;6&#x003b2;4 and &#x003b1;6&#x003b2;1 integrins associate with ErbB-2 in human carcinoma cell lines.</article-title><source>Exp. Cell Res.</source><volume>236</volume><fpage>76</fpage><lpage>85</lpage><pub-id pub-id-type="pmid">9344587</pub-id></citation></ref><ref id="pone.0001592-Guo1"><label>11</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Guo</surname><given-names>W</given-names></name><name><surname>Pylayeva</surname><given-names>Y</given-names></name><name><surname>Pepe</surname><given-names>A</given-names></name><name><surname>Yoshioka</surname><given-names>T</given-names></name><name><surname>Muller</surname><given-names>WJ</given-names></name><etal/></person-group><year>2006</year><article-title>Beta 4 integrin amplifies ErbB2 signaling to promote mammary tumorigenesis.</article-title><source>Cell</source><volume>126</volume><fpage>489</fpage><lpage>502</lpage><pub-id pub-id-type="pmid">16901783</pub-id></citation></ref><ref id="pone.0001592-Bon2"><label>12</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bon</surname><given-names>G</given-names></name><name><surname>Folgiero</surname><given-names>V</given-names></name><name><surname>Bossi</surname><given-names>G</given-names></name><name><surname>Felicioni</surname><given-names>L</given-names></name><name><surname>Marchetti</surname><given-names>A</given-names></name><etal/></person-group><year>2006</year><article-title>The loss of &#x003b2;4 integrin subunit reduces the tumorigenicity of MCF7 mammary cells and causes apoptosis upon hormone deprivation.</article-title><source>Clin Cancer Res</source><volume>12</volume><fpage>3280</fpage><lpage>3287</lpage><pub-id pub-id-type="pmid">16740748</pub-id></citation></ref><ref id="pone.0001592-Lipscomb2"><label>13</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lipscomb</surname><given-names>EA</given-names></name><name><surname>Simpson</surname><given-names>KJ</given-names></name><name><surname>Lyle</surname><given-names>SR</given-names></name><name><surname>Ring</surname><given-names>JE</given-names></name><name><surname>Dugan</surname><given-names>AS</given-names></name><etal/></person-group><year>2005</year><article-title>The alpha6beta4 integrin maintains the survival of human breast carcinoma cells in vivo.</article-title><source>Cancer Res</source><volume>65</volume><fpage>10970</fpage><lpage>10976</lpage><pub-id pub-id-type="pmid">16322245</pub-id></citation></ref><ref id="pone.0001592-Bertotti1"><label>14</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bertotti</surname><given-names>A</given-names></name><name><surname>Comoglio</surname><given-names>PM</given-names></name><name><surname>Trusolino</surname><given-names>L</given-names></name></person-group><year>2005</year><article-title>Beta4 integrin is a transforming molecule that unleashes Met tyrosine kinase tumorigenesis.</article-title><source>Cancer Res</source><volume>65</volume><fpage>10674</fpage><lpage>10679</lpage><pub-id pub-id-type="pmid">16322210</pub-id></citation></ref><ref id="pone.0001592-Folgiero1"><label>15</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Folgiero</surname><given-names>V</given-names></name><name><surname>Bachelder</surname><given-names>ER</given-names></name><name><surname>Bon</surname><given-names>G</given-names></name><name><surname>Sacchi</surname><given-names>A</given-names></name><name><surname>Falcioni</surname><given-names>R</given-names></name><etal/></person-group><year>2007</year><article-title>The &#x003b1;6&#x003b2;4 integrin can regulate ErbB-3 expression: Implications for &#x003b1;6&#x003b2;4 signaling and function.</article-title><source>Cancer Res</source><volume>67</volume><fpage>1645</fpage><lpage>1652</lpage><pub-id pub-id-type="pmid">17308105</pub-id></citation></ref><ref id="pone.0001592-Jemal1"><label>16</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Jemal</surname><given-names>A</given-names></name><name><surname>Murray</surname><given-names>T</given-names></name><name><surname>Ward</surname><given-names>E</given-names></name><name><surname>Samuels</surname><given-names>A</given-names></name><name><surname>Tiwari</surname><given-names>RC</given-names></name><etal/></person-group><year>2005</year><article-title>Cancer statistics 2005.</article-title><source>CA Cancer J. Clin</source><volume>55</volume><fpage>10</fpage><lpage>30</lpage><pub-id pub-id-type="pmid">15661684</pub-id></citation></ref><ref id="pone.0001592-Ryden1"><label>17</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ryden</surname><given-names>L</given-names></name><name><surname>Jonsson</surname><given-names>PE</given-names></name><name><surname>Chebil</surname><given-names>G</given-names></name><name><surname>Dufmats</surname><given-names>M</given-names></name><name><surname>Ferno</surname><given-names>M</given-names></name><etal/></person-group><year>2005</year><article-title>Two years of adjuvant tamoxifen in premenopausal patients with breast cancer: a randomised, controlled trial with long-term follow-up.</article-title><source>Eur. J. Cancer</source><volume>41</volume><fpage>256</fpage><lpage>264</lpage><pub-id pub-id-type="pmid">15661551</pub-id></citation></ref><ref id="pone.0001592-Osborne1"><label>18</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Osborne</surname><given-names>CK</given-names></name></person-group><year>1998</year><article-title>Tamoxifen in the treatment of breast cancer.</article-title><source>N Engl J Med</source><volume>339</volume><fpage>1609</fpage><lpage>1618</lpage><pub-id pub-id-type="pmid">9828250</pub-id></citation></ref><ref id="pone.0001592-Kuiper1"><label>19</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kuiper</surname><given-names>GG</given-names></name><name><surname>Carlsson</surname><given-names>B</given-names></name><name><surname>Grandien</surname><given-names>K</given-names></name><name><surname>Enmark</surname><given-names>E</given-names></name><name><surname>Haggblad</surname><given-names>J</given-names></name><etal/></person-group><year>1997</year><article-title>Comparison of the ligand binding specificity and transcript tissue distribution of estrogen receptors alpha and beta.</article-title><source>Endocrinology</source><volume>138</volume><fpage>863</fpage><lpage>870</lpage><pub-id pub-id-type="pmid">9048584</pub-id></citation></ref><ref id="pone.0001592-Schiff1"><label>20</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Schiff</surname><given-names>R</given-names></name><name><surname>Osborne</surname><given-names>CK</given-names></name></person-group><year>2005</year><article-title>Endocrinology and hormone therapy in breast cancer New insight into estrogen receptor-&#x003b1; function and its implication for endocrine therapy resistance in breast cancer.</article-title><source>Breast Cancer Research</source><volume>7</volume><fpage>205</fpage><lpage>211</lpage><pub-id pub-id-type="pmid">16168139</pub-id></citation></ref><ref id="pone.0001592-Grunt1"><label>21</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Grunt</surname><given-names>TW</given-names></name><name><surname>Saceda</surname><given-names>M</given-names></name><name><surname>Martin</surname><given-names>MB</given-names></name></person-group><year>1995</year><article-title>Bidirectional interactions between the estrogen receptor and the cerbB-2 signaling pathways: heregulin inhibits estrogenic effects in breast cancer cells.</article-title><source>Int J Cancer</source><volume>63</volume><fpage>560</fpage><lpage>567</lpage><pub-id pub-id-type="pmid">7591267</pub-id></citation></ref><ref id="pone.0001592-Pasleau1"><label>22</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Pasleau</surname><given-names>F</given-names></name><name><surname>Grooteclaes</surname><given-names>M</given-names></name><name><surname>Gol-Winkler</surname><given-names>R</given-names></name></person-group><year>1993</year><article-title>Expression of the c-erbB2 gene in the BT474 human mammary tumor cell line: measurement of c-erbB2 mRNA half-life.</article-title><source>Oncogene</source><volume>8</volume><fpage>849</fpage><lpage>854</lpage><pub-id pub-id-type="pmid">8096075</pub-id></citation></ref><ref id="pone.0001592-FresnoVara1"><label>23</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Fresno Vara</surname><given-names>JA</given-names></name><name><surname>Casado</surname><given-names>E</given-names></name><name><surname>de Castro</surname><given-names>J</given-names></name><name><surname>Cejas</surname><given-names>P</given-names></name><name><surname>Belda-Iniesta</surname><given-names>C</given-names></name><etal/></person-group><year>2004</year><article-title>PI3K/AKT signaling pathway and cancer.</article-title><source>Cancer Treat Review</source><volume>30</volume><fpage>193</fpage><lpage>204</lpage></citation></ref><ref id="pone.0001592-Hellyer1"><label>24</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hellyer</surname><given-names>NJ</given-names></name><name><surname>Cheng</surname><given-names>K</given-names></name><name><surname>Koland</surname><given-names>JG</given-names></name></person-group><year>1998</year><article-title>ErbB3 (HER3) interaction with the p85 regulatory subunit of phosphoinositide 3-kinase.</article-title><source>Biochem J</source><volume>333</volume><fpage>757</fpage><lpage>763</lpage><pub-id pub-id-type="pmid">9677338</pub-id></citation></ref><ref id="pone.0001592-Liu1"><label>25</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>B</given-names></name><name><surname>Ordonez-Ercan</surname><given-names>D</given-names></name><name><surname>Fan</surname><given-names>Z</given-names></name><name><surname>Edgerton</surname><given-names>SM</given-names></name><name><surname>Yang</surname><given-names>XH</given-names></name><etal/></person-group><year>2007</year><article-title>Downregulation of erbB3 abrogates erbB2-mediated tamoxifen resistance in breast cancer cells.</article-title><source>In J Cancer</source><volume>129</volume><fpage>1874</fpage><lpage>1882</lpage></citation></ref><ref id="pone.0001592-Miller1"><label>26</label><citation citation-type="book"><person-group person-group-type="author"><name><surname>Miller</surname><given-names>WR</given-names></name></person-group><year>1996</year><article-title>Prediction of estrogen sensitivity/dependence.</article-title><person-group person-group-type="editor"><name><surname>Millar</surname><given-names>MR</given-names></name></person-group><source>Estrogen and Breast Cancer</source><publisher-loc>Austin</publisher-loc><publisher-name>RG Landes Co</publisher-name><fpage>151</fpage><lpage>169</lpage></citation></ref><ref id="pone.0001592-Miller2"><label>27</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Miller</surname><given-names>WR</given-names></name><name><surname>Anderson</surname><given-names>TJ</given-names></name><name><surname>Dixon</surname><given-names>JM</given-names></name><name><surname>Saunders</surname><given-names>PT</given-names></name></person-group><year>2006</year><article-title>Oestrogen receptor beta and neoadjuvant therapy with tamoxifen: prediction of response and effects of treatment.</article-title><source>Br J Cancer</source><volume>94</volume><fpage>1333</fpage><lpage>1338</lpage><pub-id pub-id-type="pmid">16622466</pub-id></citation></ref><ref id="pone.0001592-Strom1"><label>28</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Strom</surname><given-names>A</given-names></name><name><surname>Hartman</surname><given-names>J</given-names></name><name><surname>Foster</surname><given-names>JS</given-names></name><name><surname>Kietz</surname><given-names>S</given-names></name><name><surname>Wimalasena</surname><given-names>J</given-names></name><etal/></person-group><year>2004</year><article-title>Estrogen receptor beta inhibits 17beta-estradiol-stimulated proliferation of the breast cancer cell line T47D.</article-title><source>Proc Natl Acad Sci USA</source><volume>101</volume><fpage>1566</fpage><lpage>1571</lpage><pub-id pub-id-type="pmid">14745018</pub-id></citation></ref><ref id="pone.0001592-Barnes1"><label>29</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Barnes</surname><given-names>DM</given-names></name><name><surname>Millis</surname><given-names>RR</given-names></name><name><surname>Gillett</surname><given-names>CE</given-names></name><name><surname>Ryder</surname><given-names>K</given-names></name><name><surname>Skilton</surname><given-names>D</given-names></name><etal/></person-group><year>2004</year><article-title>The interaction of oestrogen receptor status and pathological features with adjuvant treatment in relation to survival in patients with operable breast cancer: a retrospective study of 2600 patiens.</article-title><source>Endocrine-Related Cancer</source><volume>11</volume><fpage>85</fpage><lpage>96</lpage><pub-id pub-id-type="pmid">15027887</pub-id></citation></ref><ref id="pone.0001592-Lindberg1"><label>30</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lindberg</surname><given-names>MK</given-names></name><name><surname>Moverare</surname><given-names>S</given-names></name><name><surname>Skrtic</surname><given-names>S</given-names></name><name><surname>Gao</surname><given-names>H</given-names></name><name><surname>Dahlman-Wright</surname><given-names>K</given-names></name><etal/></person-group><year>2003</year><article-title>Estrogen receptor (ER)-beta reduces ERalpha regulated gene transcription, supporting a &#x02018;Ying Yang&#x02019; relationship between ERalpha and ERbeta in mice.</article-title><source>Mol Endocrinol</source><volume>17</volume><fpage>203</fpage><lpage>208</lpage><pub-id pub-id-type="pmid">12554748</pub-id></citation></ref><ref id="pone.0001592-Nicholson1"><label>31</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Nicholson</surname><given-names>RI</given-names></name><name><surname>Staka</surname><given-names>C</given-names></name><name><surname>Boyns</surname><given-names>F</given-names></name><name><surname>Hutcheson</surname><given-names>IR</given-names></name><name><surname>Gee</surname><given-names>JM</given-names></name></person-group><year>2004</year><article-title>Growth factor-driven mechanisms associated with resistance to estrogen deprivation in breast cancer: new opportunities for therapy.</article-title><source>Endocrine-Related Cancer</source><volume>11</volume><fpage>623</fpage><lpage>629</lpage><pub-id pub-id-type="pmid">15613443</pub-id></citation></ref><ref id="pone.0001592-Friedrichs1"><label>32</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Friedrichs</surname><given-names>K</given-names></name><name><surname>Ruiz</surname><given-names>P</given-names></name><name><surname>Franke</surname><given-names>F</given-names></name><name><surname>Gille</surname><given-names>I</given-names></name><name><surname>Terpe</surname><given-names>HJ</given-names></name><etal/></person-group><year>1995</year><article-title>High expression level of &#x003b1;6 integrin in human breast carcinoma is correlated with reduced survival.</article-title><source>Cancer Res</source><volume>55</volume><fpage>901</fpage><lpage>906</lpage><pub-id pub-id-type="pmid">7850807</pub-id></citation></ref><ref id="pone.0001592-Tagliabue1"><label>33</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Tagliabue</surname><given-names>E</given-names></name><name><surname>Ghirelli</surname><given-names>C</given-names></name><name><surname>Squicciarini</surname><given-names>P</given-names></name><name><surname>Aiello</surname><given-names>P</given-names></name><name><surname>Colnaghi</surname><given-names>MI</given-names></name><etal/></person-group><year>1998</year><article-title>Prognostic value of &#x003b1;6&#x003b2;4 integrin expression in breast carcinomas is affected by laminin production from tumor cells.</article-title><source>Clin Cancer Res</source><volume>4</volume><fpage>407</fpage><lpage>410</lpage><pub-id pub-id-type="pmid">9516929</pub-id></citation></ref><ref id="pone.0001592-Perou1"><label>34</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Perou</surname><given-names>CM</given-names></name><name><surname>Sorlie</surname><given-names>T</given-names></name><name><surname>Elsen</surname><given-names>MB</given-names></name><name><surname>van de Rijn</surname><given-names>M</given-names></name><name><surname>Jeffrey</surname><given-names>SS</given-names></name><etal/></person-group><year>2000</year><article-title>Molecular portraits of human breast tumors.</article-title><source>Nature</source><volume>406</volume><fpage>747</fpage><lpage>752</lpage><pub-id pub-id-type="pmid">10963602</pub-id></citation></ref><ref id="pone.0001592-Chung1"><label>35</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Chung</surname><given-names>J</given-names></name><name><surname>Bachelder</surname><given-names>RE</given-names></name><name><surname>Lipscomb</surname><given-names>EA</given-names></name><name><surname>Shaw</surname><given-names>LM</given-names></name><name><surname>Mercurio</surname><given-names>AM</given-names></name></person-group><year>2002</year><article-title>Integrin (alpha6beta4) regulation of eIF-4E activity and VEGF translation: a survival mechanism for carcinoma cells.</article-title><source>J Cell Biol</source><volume>158</volume><fpage>165</fpage><lpage>174</lpage><pub-id pub-id-type="pmid">12105188</pub-id></citation></ref><ref id="pone.0001592-Naidu1"><label>36</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Naidu</surname><given-names>R</given-names></name><name><surname>Yadav</surname><given-names>M</given-names></name><name><surname>Nair</surname><given-names>S</given-names></name><name><surname>Kutty</surname><given-names>MK</given-names></name></person-group><year>1998</year><article-title>Expression of c-erbB3 protein in primary breast carcinomas.</article-title><source>Br. J. Cancer</source><volume>78</volume><fpage>1385</fpage><lpage>1390</lpage><pub-id pub-id-type="pmid">9823984</pub-id></citation></ref><ref id="pone.0001592-Witton1"><label>37</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Witton</surname><given-names>CJ</given-names></name><name><surname>Reeves</surname><given-names>JR</given-names></name><name><surname>Going</surname><given-names>JJ</given-names></name><name><surname>Cooke</surname><given-names>TG</given-names></name><name><surname>Bartlett</surname><given-names>JM</given-names></name></person-group><year>2003</year><article-title>Expression of HER1-4 family receptor tyrosine kinases in breast cancer.</article-title><source>J Pathol</source><volume>200</volume><fpage>279</fpage><lpage>287</lpage><pub-id pub-id-type="pmid">12845622</pub-id></citation></ref><ref id="pone.0001592-Hopp1"><label>38</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hopp</surname><given-names>TA</given-names></name><name><surname>Weiss</surname><given-names>HL</given-names></name><name><surname>Parra</surname><given-names>IS</given-names></name><name><surname>Cui</surname><given-names>Y</given-names></name><name><surname>Osborne</surname><given-names>CK</given-names></name><etal/></person-group><year>2004</year><article-title>Low levels of estrogen receptor &#x003b2; protein.</article-title><source>Clin Cancer Res</source><volume>10</volume><fpage>7490</fpage><lpage>7499</lpage><pub-id pub-id-type="pmid">15569979</pub-id></citation></ref><ref id="pone.0001592-Langhofer1"><label>39</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Langhofer</surname><given-names>M</given-names></name><name><surname>Hopkinson</surname><given-names>SB</given-names></name><name><surname>Jones</surname><given-names>JC</given-names></name></person-group><year>1993</year><article-title>The matrix secreted by 804G cells contains laminin-related components that participate in hemidesmosome assembly in vitro.</article-title><source>J Cell Sci</source><volume>105</volume><fpage>753</fpage><lpage>764</lpage><pub-id pub-id-type="pmid">8408302</pub-id></citation></ref><ref id="pone.0001592-CampbellThompson1"><label>40</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Campbell-Thompson</surname><given-names>M</given-names></name><name><surname>Lynch</surname><given-names>IJ</given-names></name><name><surname>Bhardwaj</surname><given-names>B</given-names></name></person-group><year>2001</year><article-title>Expression of estrogen receptor (ER) subtypes and ER&#x003b2;1 isoforms in colon cancer.</article-title><source>Cancer Res.</source><volume>61</volume><fpage>632</fpage><lpage>40</lpage><pub-id pub-id-type="pmid">11212261</pub-id></citation></ref><ref id="pone.0001592-Travasoli1"><label>41</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Travasoli</surname><given-names>FA</given-names></name></person-group><year>2005</year><article-title>Breast pathology: rationale for adopting the ductal intraepithelial neoplasia (DIN) classification.</article-title><source>Nature Clin Practice Oncol</source><volume>2</volume><fpage>116</fpage><lpage>117</lpage></citation></ref></ref-list><fn-group><fn fn-type="conflict"><p><bold>Competing Interests: </bold>The authors have declared that no competing interests exist.</p></fn><fn fn-type="financial-disclosure"><p><bold>Funding: </bold>This study was supported by Grant: Italian Association for Cancer Research and Ministero della Salute (R. Falcioni, M. Mottolese); Alleanza contro il Cancro (M. Mottolese); G. Bon is recipient of a fellowship from Federazione Italiana Ricerca sul Cancro (FIRC).</p></fn></fn-group></back></article> 